

# Salim Yusuf

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9468106/publications.pdf>

Version: 2024-02-01

1,035  
papers

199,581  
citations

16

205  
h-index

34

423  
g-index

1079  
all docs

1079  
docs citations

1079  
times ranked

105287  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2009, 361, 1139-1151.	13.9	9,839
2	Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. <i>Lancet</i> , The, 2004, 364, 937-952.	6.3	9,716
3	Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. <i>New England Journal of Medicine</i> , 1991, 325, 293-302.	13.9	6,773
4	Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. <i>New England Journal of Medicine</i> , 2008, 358, 1547-1559.	13.9	3,155
5	Beta blockade during and after myocardial infarction: An overview of the randomized trials. <i>Progress in Cardiovascular Diseases</i> , 1985, 27, 335-371.	1.6	3,047
6	Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. <i>Lancet</i> , The, 2001, 358, 527-533.	6.3	2,914
7	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <i>Lancet</i> , The, 2003, 362, 777-781.	6.3	2,584
8	Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	6.3	2,565
9	Obesity and the risk of myocardial infarction in 27â€™000 participants from 52 countries: a case-control study. <i>Lancet</i> , The, 2005, 366, 1640-1649.	6.3	2,414
10	Global Burden of Cardiovascular Diseases. <i>Circulation</i> , 2001, 104, 2746-2753.	1.6	2,337
11	Apixaban in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 806-817.	13.9	2,207
12	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. <i>Lancet</i> , The, 2003, 362, 767-771.	6.3	1,978
13	Association of psychosocial risk factors with risk of acute myocardial infarction in 11â€™119 cases and 13â€™648 controls from 52 countries (the INTERHEART study): case-control study. <i>Lancet</i> , The, 2004, 364, 953-962.	6.3	1,858
14	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. <i>Lancet</i> , The, 2011, 377, 1409-1420.	6.3	1,759
15	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet</i> , The, 2003, 362, 759-766.	6.3	1,752
16	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
17	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet</i> , The, 2003, 362, 772-776.	6.3	1,623
18	Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. <i>New England Journal of Medicine</i> , 2006, 354, 1567-1577.	13.9	1,536

#	ARTICLE	IF	CITATIONS
19	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET) Tj ETQq1 1 0.784314 rgBT/Overlook	6.3	1,442
20	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. <i>New England Journal of Medicine</i> , 2012, 367, 319-328.	13.9	1,426
21	Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 959.	3.8	1,422
22	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. <i>Lancet, The</i> , 2016, 388, 761-775.	6.3	1,414
23	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet, The</i> , 2016, 388, 2532-2561.	6.3	1,399
24	Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. <i>Lancet, The</i> , 2000, 355, 1575-1581.	6.3	1,398
25	The burden of disease in older people and implications for health policy and practice. <i>Lancet, The</i> , 2015, 385, 549-562.	6.3	1,393
26	Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous Heparin. <i>New England Journal of Medicine</i> , 1988, 318, 1162-1173.	13.9	1,334
27	Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. <i>Lancet, The</i> , 2015, 386, 266-273.	6.3	1,295
28	Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. <i>Annals of Internal Medicine</i> , 2001, 134, 629.	2.0	1,243
29	Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2006, 114, 774-782.	1.6	1,196
30	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. <i>Nature Genetics</i> , 2018, 50, 524-537.	9.4	1,124
31	Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2006, 354, 1464-1476.	13.9	1,104
32	Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1338.	3.8	1,083
33	Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events. <i>Circulation</i> , 2002, 105, 1650-1655.	1.6	1,040
34	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 2363-2372.	1.6	1,035
35	Global Burden of Cardiovascular Diseases. <i>Circulation</i> , 2001, 104, 2855-2864.	1.6	993
36	Modifiable risk factors, cardiovascular disease, and mortality in 155~722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. <i>Lancet, The</i> , 2020, 395, 795-808.	6.3	935

#	ARTICLE	IF	CITATIONS
37	Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: A systematic review and meta-analysis of randomized trials. <i>American Heart Journal</i> , 2009, 157, 132-140.	1.2	920
38	Emerging Epidemic of Cardiovascular Disease in Developing Countries. <i>Circulation</i> , 1998, 97, 596-601.	1.6	915
39	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet</i> , The, 2010, 376, 975-983.	6.3	913
40	Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke. <i>New England Journal of Medicine</i> , 2008, 359, 1238-1251.	13.9	882
41	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). <i>Lancet</i> , The, 2000, 356, 279-284.	6.3	866
42	Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. <i>Lancet</i> , The, 2017, 390, 2050-2062.	6.3	841
43	The effect of physical activity on mortality and cardiovascular disease in 130,000 people from 17 high-income, middle-income, and low-income countries: the PURE study. <i>Lancet</i> , The, 2017, 390, 2643-2654.	6.3	838
44	Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1519-1530.	3.8	830
45	Predictors of mortality and morbidity in patients with chronic heart failure. <i>European Heart Journal</i> , 2006, 27, 65-75.	1.0	822
46	Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 671-678.	1.6	817
47	n-3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. <i>New England Journal of Medicine</i> , 2012, 367, 309-318.	13.9	810
48	Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 40-47.	1.2	809
49	Randomized Trial of Benznidazole for Chronic Chagas's Cardiomyopathy. <i>New England Journal of Medicine</i> , 2015, 373, 1295-1306.	13.9	807
50	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. <i>Lancet</i> , The, 2011, 378, 1231-1243.	6.3	803
51	Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. <i>Lancet</i> , The, 2006, 368, 647-658.	6.3	802
52	Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. <i>Circulation</i> , 2008, 118, 2029-2037.	1.6	789
53	Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence. <i>Annals of Internal Medicine</i> , 1999, 131, 363.	2.0	781
54	Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non-ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2004, 110, 1202-1208.	1.6	778

#	ARTICLE	IF	CITATIONS
55	ACC/AHA guidelines for coronary artery bypass graft surgery. Journal of the American College of Cardiology, 1999, 34, 1262-1347.	1.2	775
56	Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Journal of the American College of Cardiology, 2005, 45, 1832-1839.	1.2	774
57	Cardiovascular sequelae of preeclampsia/eclampsia: A systematic review and meta-analyses. American Heart Journal, 2008, 156, 918-930.	1.2	767
58	Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney International, 2011, 79, 1341-1352.	2.6	759
59	Early versus Delayed Invasive Intervention in Acute Coronary Syndromes. New England Journal of Medicine, 2009, 360, 2165-2175.	13.9	748
60	Myocardial Injury after Noncardiac Surgery. Anesthesiology, 2014, 120, 564-578.	1.3	740
61	Aspirin in Patients Undergoing Noncardiac Surgery. New England Journal of Medicine, 2014, 370, 1494-1503.	13.9	735
62	The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. Journal of the American College of Cardiology, 2014, 63, 321-328.	1.2	733
63	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet, The, 2010, 376, 1233-1243.	6.3	725
64	Urinary Sodium and Potassium Excretion, Mortality, and Cardiovascular Events. New England Journal of Medicine, 2014, 371, 612-623.	13.9	725
65	Routine vs Selective Invasive Strategies in Patients With Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2005, 293, 2908.	3.8	717
66	Risk Factors for Early Myocardial Infarction in South Asians Compared With Individuals in Other Countries. JAMA - Journal of the American Medical Association, 2007, 297, 286.	3.8	705
67	Effects of Physiologic Pacing versus Ventricular Pacing on the Risk of Stroke and Death Due to Cardiovascular Causes. New England Journal of Medicine, 2000, 342, 1385-1391.	13.9	704
68	Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events. New England Journal of Medicine, 2008, 359, 1225-1237.	13.9	703
69	Why do we need some large, simple randomized trials?. Statistics in Medicine, 1984, 3, 409-420.	0.8	700
70	Effects of Ramipril and Vitamin E on Atherosclerosis. Circulation, 2001, 103, 919-925.	1.6	698
71	Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the Tj ETQq1 1 0.784314 rgBT /Overlo	6.3	693
72	Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non-Q-Wave Myocardial Infarction. Circulation, 2000, 102, 1014-1019.	1.6	688

#	ARTICLE	IF	CITATIONS
73	Association of Urinary Sodium and Potassium Excretion with Blood Pressure. <i>New England Journal of Medicine</i> , 2014, 371, 601-611.	13.9	687
74	Effect of Ramipril on the Incidence of Diabetes. <i>New England Journal of Medicine</i> , 2006, 355, 1551-1562.	13.9	684
75	Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 108, 1682-1687.	1.6	682
76	Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2010, 363, 930-942.	13.9	681
77	Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries. <i>New England Journal of Medicine</i> , 2014, 371, 818-827.	13.9	679
78	Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients. <i>Circulation</i> , 2005, 112, 3738-3744.	1.6	678
79	Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. <i>European Heart Journal</i> , 2008, 29, 932-940.	1.0	652
80	Newly Identified Events in the RE-LY Trial. <i>New England Journal of Medicine</i> , 2010, 363, 1875-1876.	13.9	652
81	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 219-229.	6.3	651
82	Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. <i>Lancet, The</i> , 2003, 361, 1077-1083.	6.3	648
83	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2021-2031.	13.9	641
84	Reducing the Global Burden of Cardiovascular Disease, Part 1. <i>Circulation Research</i> , 2017, 121, 677-694.	2.0	639
85	Off-Pump or On-Pump Coronary-Artery Bypass Grafting at 30 Days. <i>New England Journal of Medicine</i> , 2012, 366, 1489-1497.	13.9	620
86	Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 437.	3.8	581
87	Characteristics and Short-Term Prognosis of Perioperative Myocardial Infarction in Patients Undergoing Noncardiac Surgery. <i>Annals of Internal Medicine</i> , 2011, 154, 523.	2.0	557
88	Association of Diet, Exercise, and Smoking Modification With Risk of Early Cardiovascular Events After Acute Coronary Syndromes. <i>Circulation</i> , 2010, 121, 750-758.	1.6	556
89	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 1377-1385.	1.0	549
90	Dronedronone in High-Risk Permanent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 2268-2276.	13.9	547

#	ARTICLE	IF	CITATIONS
91	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. <i>New England Journal of Medicine</i> , 2015, 372, 1389-1398.	13.9	536
92	Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 1482-1487.	1.6	528
93	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2009-2020.	13.9	526
94	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , 2019, 393, 407-415.	6.3	512
95	Atrial Fibrillation and Risk of Clinical Events in Chronic Heart Failure With and Without Left Ventricular Systolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1997-2004.	1.2	507
96	Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril. <i>Circulation</i> , 2001, 104, 1615-1621.	1.6	502
97	Effects of <i>CYP2C19</i> Genotype on Outcomes of Clopidogrel Treatment. <i>New England Journal of Medicine</i> , 2010, 363, 1704-1714.	13.9	497
98	The Prospective Urban Rural Epidemiology (PURE) study: Examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. <i>American Heart Journal</i> , 2009, 158, 1-7.e1.	1.2	495
99	Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin. <i>Circulation</i> , 2012, 126, 343-348.	1.6	494
100	Ramipril and the Development of Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 1882.	3.8	487
101	Defining Obesity Cut Points in a Multiethnic Population. <i>Circulation</i> , 2007, 115, 2111-2118.	1.6	476
102	Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2229-38.	3.8	471
103	Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. <i>Lancet, The</i> , 2008, 371, 1435-1442.	6.3	463
104	Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. <i>Lancet, The</i> , 2006, 368, 581-588.	6.3	456
105	Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. <i>Circulation</i> , 2013, 127, 634-640.	1.6	447
106	Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. <i>Circulation</i> , 2011, 123, 131-136.	1.6	446
107	Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. <i>Lancet, The</i> , 2017, 390, 2037-2049.	6.3	446
108	Interventions on Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Heart Surgery. <i>Circulation</i> , 2002, 106, 75-80.	1.6	442



#	ARTICLE	IF	CITATIONS
109	Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. <i>American Journal of Cardiology</i> , 1996, 77, 1017-1020.	0.7	440
110	Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. <i>Lancet</i> , The, 2020, 395, 785-794.	6.3	428
111	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2018, 391, 205-218.	6.3	426
112	Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2156-2161.	1.2	422
113	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. <i>Lancet</i> , The, 2000, 355, 1936-1942.	6.3	419
114	Overcoming the limitations of current meta-analysis of randomised controlled trials. <i>Lancet</i> , The, 1998, 351, 47-52.	6.3	415
115	Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. <i>Nature Genetics</i> , 2010, 42, 684-687.	9.4	414
116	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. <i>Lancet</i> , The, 2021, 397, 1625-1636.	6.3	414
117	Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures. <i>Hypertension</i> , 2001, 38, E28-32.	1.3	405
118	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neurology</i> , The, 2010, 9, 1157-1163.	4.9	399
119	Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). <i>European Heart Journal</i> , 2015, 36, 1115-1122.	1.0	391
120	Effects of Off-Pump and On-Pump Coronary-Artery Bypass Grafting at 1 Year. <i>New England Journal of Medicine</i> , 2013, 368, 1179-1188.	13.9	390
121	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet</i> , The, 2016, 387, 2302-2311.	6.3	389
122	Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran. <i>Stroke</i> , 2012, 43, 1511-1517.	1.0	385
123	Oral Anticoagulant and Antiplatelet Therapy and Peripheral Arterial Disease. <i>New England Journal of Medicine</i> , 2007, 357, 217-227.	13.9	383
124	ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: Executive Summary and Recommendations. <i>Circulation</i> , 1999, 100, 1464-1480.	1.6	376
125	Dietary Patterns and the Risk of Acute Myocardial Infarction in 52 Countries. <i>Circulation</i> , 2008, 118, 1929-1937.	1.6	367
126	Novel therapeutic concepts * The epidemic of cardiovascular disease in the developing world: global implications. <i>European Heart Journal</i> , 2010, 31, 642-648.	1.0	366



#	ARTICLE	IF	CITATIONS
127	Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction <sup>11</sup> Drs. Mehta and Eikelboom were recipients of Heart and Stroke Foundation of Canada Research Fellowship Awards. Professor Yusuf is the recipient of a Medical Research Council of Canada Senior Scientist Award and holds a Heart and Stroke Foundation of Ontario Research Chair. <i>Journal of the American College of Cardiology</i> , 2001, 37, 37-43.	1.2	364
128	Cumulating evidence from randomized trials: Utilizing sequential monitoring boundaries for cumulative meta-analysis. <i>Contemporary Clinical Trials</i> , 1997, 18, 580-593.	2.0	359
129	Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes: Results of the HOPE Study and MICRO-HOPE Substudy. <i>Diabetes Care</i> , 2002, 25, 1919-1927.	4.3	349
130	Effects of Radial Versus Femoral Artery Access in Patients With Acute Coronary Syndromes With or Without ST-Segment Elevation. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2490-2499.	1.2	349
131	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. <i>Circulation</i> , 2012, 125, 669-676.	1.6	348
132	Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2004, 110, 2618-2626.	1.6	347
133	Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2012, 125, 1605-1616.	1.6	346
134	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 961-970.	1.6	346
135	Two decades of progress in preventing vascular disease. <i>Lancet, The</i> , 2002, 360, 2-3.	6.3	344
136	Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1590-1614.	1.2	343
137	Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. <i>Lancet, The</i> , 1998, 352, 507-514.	6.3	340
138	Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. <i>Lancet, The</i> , 2003, 361, 1843-1848.	6.3	340
139	Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. <i>The Lancet Global Health</i> , 2019, 7, e748-e760.	2.9	340
140	Body Mass Index and Prognosis in Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 627-636.	1.6	328
141	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009, 11, 170-177.	2.9	326
142	Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , 2016, 375, 2359-2368.	13.9	326
143	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. <i>Circulation</i> , 2014, 129, 1568-1576.	1.6	324
144	Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. <i>New England Journal of Medicine</i> , 2021, 384, 2081-2091.	13.9	321

#	ARTICLE	IF	CITATIONS
145	Principles for National and Regional Guidelines on Cardiovascular Disease Prevention. <i>Circulation</i> , 2004, 109, 3112-3121.	1.6	314
146	Baseline Quality of Life as a Predictor of Mortality and Hospitalization in 5,025 Patients With Congestive Heart Failure. <i>American Journal of Cardiology</i> , 1996, 78, 890-895.	0.7	313
147	Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) trial: a double-blind, active and placebo-controlled study. <i>Lancet Neurology</i> , The, 2008, 7, 875-884.	4.9	310
148	Prognostic Significance of Plasma Norepinephrine in Patients With Asymptomatic Left Ventricular Dysfunction. <i>Circulation</i> , 1996, 94, 690-697.	1.6	305
149	Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations. <i>Journal of the American College of Cardiology</i> , 2020, 76, 844-857.	1.2	302
150	Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study. <i>Journal of the American College of Cardiology</i> , 1992, 20, 1056-1062.	1.2	301
151	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2016, 374, 2032-2043.	13.9	299
152	Risk Factors Associated With Myocardial Infarction in Africa. <i>Circulation</i> , 2005, 112, 3554-3561.	1.6	298
153	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology</i> , the, 2017, 5, 97-105.	5.5	298
154	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2306-2315.	1.2	296
155	Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. <i>American Heart Journal</i> , 2005, 149, 54-60.	1.2	295
156	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018, 20, 1230-1239.	2.9	295
157	Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. <i>Lancet</i> , The, 2018, 392, 2288-2297.	6.3	295
158	Dabigatran Versus Warfarin. <i>Stroke</i> , 2013, 44, 1891-1896.	1.0	292
159	Does PTCA in Acute Myocardial Infarction Affect Mortality and Reinfarction Rates?. <i>Circulation</i> , 1995, 91, 476-485.	1.6	289
160	Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: findings from the Prospective Urban Rural Epidemiology (PURE) study. <i>The Lancet Global Health</i> , 2016, 4, e695-e703.	2.9	287
161	Early and Late Effects of Clopidogrel in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2003, 107, 966-972.	1.6	285
162	Clonidine in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2014, 370, 1504-1513.	13.9	285

#	ARTICLE	IF	CITATIONS
163	Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. <i>European Journal of Heart Failure</i> , 2005, 7, 1133-1144.	2.9	283
164	Patient and Healthcare Provider Barriers to Hypertension Awareness, Treatment and Follow Up: A Systematic Review and Meta-Analysis of Qualitative and Quantitative Studies. <i>PLoS ONE</i> , 2014, 9, e84238.	1.1	282
165	Effects of exercise training in patients with heart failure: The Exercise Rehabilitation Trial (EXERT). <i>American Heart Journal</i> , 2002, 144, 23-30.	1.2	275
166	Risk Factors for Acute Myocardial Infarction in Latin America. <i>Circulation</i> , 2007, 115, 1067-1074.	1.6	273
167	Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. <i>Lancet, The</i> , 2016, 387, 61-69.	6.3	272
168	Causes of Death and Influencing Factors in Patients With Atrial Fibrillation. <i>Circulation</i> , 2013, 128, 2192-2201.	1.6	268
169	Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2015, 386, 1243-1253.	6.3	268
170	Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. <i>American Heart Journal</i> , 2001, 142, 698-703.	1.2	264
171	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017, 389, 2226-2237.	6.3	263
172	Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and design. <i>Journal of Cardiac Failure</i> , 1999, 5, 276-282.	0.7	260
173	Update of effects of calcium antagonists in myocardial infarction or angina in light of the second danish verapamil infarction trial (DAVIT-II) and other recent studies. <i>American Journal of Cardiology</i> , 1991, 67, 1295-1297.	0.7	259
174	Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). <i>Lancet, The</i> , 2001, 358, 1147-1153.	6.3	257
175	Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease. <i>Circulation</i> , 2003, 108, 420-425.	1.6	257
176	Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin. <i>Circulation</i> , 2013, 128, 2325-2332.	1.6	257
177	Prevalence of a Healthy Lifestyle Among Individuals With Cardiovascular Disease in High-, Middle- and Low-Income Countries. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1613.	3.8	256
178	Reducing the Global Burden of Cardiovascular Disease, Part 2. <i>Circulation Research</i> , 2017, 121, 695-710.	2.0	256
179	Differences in the Management and Prognosis of Women and Men Who Suffer From Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1845-1851.	1.2	255
180	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1742-1751.	1.2	253

#	ARTICLE	IF	CITATIONS
181	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. <i>Nature Genetics</i> , 2022, 54, 560-572.	9.4	250
182	Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. <i>The Lancet Global Health</i> , 2017, 5, e665-e672.	2.9	247
183	Risk factors for acute myocardial infarction in Indians: a case-control study. <i>Lancet, The</i> , 1996, 348, 358-363.	6.3	246
184	Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. <i>Lancet, The</i> , 2018, 392, 496-506.	6.3	243
185	Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients. <i>Circulation</i> , 2004, 110, 2180-2183.	1.6	241
186	Albuminuria in chronic heart failure: prevalence and prognostic importance. <i>Lancet, The</i> , 2009, 374, 543-550.	6.3	239
187	Cardiovascular Outcomes With Atrial-Based Pacing Compared With Ventricular Pacing. <i>Circulation</i> , 2006, 114, 11-17.	1.6	238
188	Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2018, 391, 2325-2334.	6.3	236
189	Sex Differences in Clinical Characteristics and Prognosis in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2007, 115, 3111-3120.	1.6	235
190	Changes in Albuminuria Predict Mortality and Morbidity in Patients with Vascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1353-1364.	3.0	234
191	Prednisolone and <i>Mycobacterium indicus pranii</i> in Tuberculous Pericarditis. <i>New England Journal of Medicine</i> , 2014, 371, 1121-1130.	13.9	233
192	Thrombus Aspiration in ST-Segmentâ€“Elevation Myocardial Infarction. <i>Circulation</i> , 2017, 135, 143-152.	1.6	233
193	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. <i>Circulation</i> , 2020, 142, 621-642.	1.6	232
194	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. <i>Lancet, The</i> , 2002, 360, 1037-1043.	6.3	230
195	The DREAM trial â€“ Authors' reply. <i>Lancet, The</i> , 2006, 368, 2050-2051.	6.3	230
196	Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure. <i>Circulation</i> , 2006, 113, 986-994.	1.6	229
197	Is a Pre-Operative Brain Natriuretic Peptide or N-Terminal Proâ€“B-Type Natriuretic Peptide Measurement an Independent Predictor of Adverse Cardiovascular Outcomes Within 30 Days of Noncardiac Surgery?. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1599-1606.	1.2	227
198	Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. <i>American Journal of Human Genetics</i> , 2012, 91, 823-838.	2.6	227

#	ARTICLE	IF	CITATIONS
199	Effect of Intravenous Streptokinase on Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 1982, 307, 1180-1182.	13.9	226
200	Increased winter mortality from acute myocardial infarction and stroke: the effect of age. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1916-1919.	1.2	226
201	Benefit of Clopidogrel in Patients With Acute Coronary Syndromes Without ST-Segment Elevation in Various Risk Groups. <i>Circulation</i> , 2002, 106, 1622-1626.	1.6	224
202	Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding. <i>Circulation</i> , 2013, 127, 1404-1412.	1.6	222
203	Blood-pressure reduction and cardiovascular risk in HOPE study. <i>Lancet, The</i> , 2001, 358, 2130-2131.	6.3	220
204	Irbesartan in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 364, 928-938.	13.9	220
205	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet, The</i> , 2016, 388, 1161-1169.	6.3	216
206	Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2137-44.	3.8	215
207	Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries. <i>Circulation</i> , 2016, 134, 1456-1466.	1.6	213
208	Prevalence of coronary artery disease in Asian Indians. <i>American Journal of Cardiology</i> , 1992, 70, 945-949.	0.7	211
209	Strengths and limitations of meta-analysis: Larger studies may be more reliable. <i>Contemporary Clinical Trials</i> , 1997, 18, 568-579.	2.0	211
210	Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. <i>Circulation</i> , 2005, 112, 48-53.	1.6	211
211	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. <i>European Heart Journal</i> , 2013, 34, 3137-3144.	1.0	211
212	Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. <i>European Heart Journal</i> , 2019, 40, 1620-1629.	1.0	208
213	Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , 1994, 23, 1410-1420.	1.2	207
214	Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , 2003, 107, 1284-1290.	1.6	207
215	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. <i>European Heart Journal</i> , 2011, 32, 581-589.	1.0	199
216	Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. <i>Lancet, The</i> , 2020, 395, 698-708.	6.3	199

#	ARTICLE	IF	CITATIONS
217	Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 774-787.	5.5	198
218	Metabolic Syndrome and Risk of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2390-2398.	1.2	197
219	Changes in Renal Function in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2481-2493.	1.2	197
220	Stemming the global tsunami of cardiovascular disease. <i>Lancet, The</i> , 2011, 377, 529-532.	6.3	196
221	Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. <i>Circulation</i> , 2019, 139, 1472-1482.	1.6	196
222	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , 2013, 128, 237-243.	1.6	195
223	Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. <i>Lancet, The</i> , 2020, 396, 97-109.	6.3	194
224	Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural epidemiologic (PURE) study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2016, 7, 535-546.	2.9	191
225	Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. <i>European Journal of Heart Failure</i> , 2007, 9, 83-91.	2.9	188
226	WHO study on Prevention of REcurrences of Myocardial Infarction and Stroke (WHO-PREMISE). <i>Bulletin of the World Health Organization</i> , 2005, 83, 820-9.	1.5	188
227	Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. <i>Lancet, The</i> , 2016, 387, 127-135.	6.3	187
228	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to <sc>CHARM</sc>â€Preserved. <i>European Journal of Heart Failure</i> , 2014, 16, 33-40.	2.9	186
229	Canadian Trial of Physiological Pacing. <i>Circulation</i> , 2004, 109, 357-362.	1.6	184
230	Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. <i>Journal of the American College of Cardiology</i> , 2001, 38, 806-813.	1.2	183
231	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). <i>American Heart Journal</i> , 2008, 156, 37-43.	1.2	183
232	Lipid Profile, Plasma Apolipoproteins, and Risk of a First Myocardial Infarction Among Asians. <i>Journal of the American College of Cardiology</i> , 2009, 53, 244-253.	1.2	182
233	Effects of Ramipril on Coronary Events in High-Risk Persons. <i>Circulation</i> , 2001, 104, 522-526.	1.6	181
234	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial. <i>Annals of Internal Medicine</i> , 2011, 155, 660.	2.0	181



#	ARTICLE	IF	CITATIONS
235	Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2152-2163.	1.2	181
236	C-Reactive Protein as a Screening Test for Cardiovascular Risk in a Multiethnic Population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 1509-1515.	1.1	179
237	Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk. <i>Stroke</i> , 2008, 39, 1482-1486.	1.0	177
238	Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. <i>Lancet Neurology</i> , The, 2011, 10, 43-53.	4.9	177
239	Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes. <i>Circulation</i> , 2005, 112, 1339-1346.	1.6	172
240	Erectile Dysfunction Predicts Cardiovascular Events in High-Risk Patients Receiving Telmisartan, Ramipril, or Both. <i>Circulation</i> , 2010, 121, 1439-1446.	1.6	172
241	Kidney Function After Off-Pump or On-Pump Coronary Artery Bypass Graft Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2191.	3.8	167
242	Homocysteine and Coronary Heart Disease: Meta-analysis of MTHFR Case-Control Studies, Avoiding Publication Bias. <i>PLoS Medicine</i> , 2012, 9, e1001177.	3.9	167
243	Effects of exercise training in patients with congestive heart failure: A critical review. <i>Journal of the American College of Cardiology</i> , 1995, 25, 789-796.	1.2	165
244	Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. <i>BMJ: British Medical Journal</i> , 1996, 313, 652-659.	2.4	165
245	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008, 29, 2641-2650.	1.0	164
246	Safety and Efficacy of Low Blood Pressures Among Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 74-83.	1.2	164
247	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. <i>Lancet Neurology</i> , The, 2012, 11, 225-231.	4.9	164
248	Effect of Telmisartan on Renal Outcomes. <i>Annals of Internal Medicine</i> , 2009, 151, 1.	2.0	163
249	Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. <i>Lancet</i> , The, 2015, 386, 1945-1954.	6.3	163
250	Polypill with or without Aspirin in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 216-228.	13.9	163
251	Rationale, Design and Baseline Data of a Randomized, Double-Blind, Controlled Trial Comparing Two Antithrombotic Regimens (a Fixed-Dose Combination of Extended-Release Dipyridamole plus ASA with) Effectively Avoiding Second Strokes Trial (PROFESS). <i>Cerebrovascular Diseases</i> , 2007, 23, 368-380.	11.0	162
252	Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , 2005, 45, 391-399.	1.2	161



#	ARTICLE	IF	CITATIONS
253	Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux: The FUTURA/OASIS-8 Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1339-1349.	3.8	161
254	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , 2013, 34, 170-176.	1.0	160
255	Dabigatran and Warfarin in Vitamin K Antagonist-“Naive and “Experienced Cohorts With Atrial Fibrillation. <i>Circulation</i> , 2010, 122, 2246-2253.	1.6	158
256	Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , 2001, 37, 1677-1682.	1.2	157
257	Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin. <i>Journal of the American College of Cardiology</i> , 2000, 35, 1801-1807.	1.2	156
258	Blood Pressure Targets Recommended by Guidelines and Incidence of Cardiovascular and Renal Events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). <i>Circulation</i> , 2011, 124, 1727-1736.	1.6	156
259	Incidence and Predictors of Hyperkalemia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1959-1966.	1.2	153
260	Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance. <i>Diabetes Care</i> , 2010, 33, 1629-1634.	4.3	152
261	The Polypill in the Prevention of Cardiovascular Diseases. <i>Circulation</i> , 2010, 122, 2078-2088.	1.6	152
262	Sodium Intake and Cardiovascular Health. <i>Circulation Research</i> , 2015, 116, 1046-1057.	2.0	152
263	Relationship Between Healthy Diet and Risk of Cardiovascular Disease Among Patients on Drug Therapies for Secondary Prevention. <i>Circulation</i> , 2012, 126, 2705-2712.	1.6	151
264	Early cerebral small vessel disease and brain volume, cognition, and gait. <i>Annals of Neurology</i> , 2015, 77, 251-261.	2.8	150
265	Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , 1994, 23, 393-400.	1.2	149
266	Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2399.	3.8	149
267	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , 2008, 30, 655-661.	1.0	149
268	Revascularization for Unprotected Left Main Stem Coronary Artery Stenosis. <i>Journal of the American College of Cardiology</i> , 2008, 51, 885-892.	1.2	148
269	From the hope to the ontarget and the transcend studies: challenges in improving prognosis. <i>American Journal of Cardiology</i> , 2002, 89, 18-25.	0.7	146
270	Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1785-1795.	1.2	146

#	ARTICLE	IF	CITATIONS
271	Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. <i>Lancet, The</i> , 2019, 394, 1022-1029.	6.3	146
272	Specific barriers to the conduct of randomized trials. <i>Clinical Trials</i> , 2008, 5, 40-48.	0.7	144
273	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2011, 162, 900-906.	1.2	143
274	Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina. <i>Circulation</i> , 2003, 108, 2439-2445.	1.6	141
275	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease. <i>Circulation</i> , 2016, 134, 589-598.	1.6	140
276	Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. <i>Diabetes Care</i> , 2016, 39, 780-787.	4.3	138
277	Effects of Reviparin, a Low-Molecular-Weight Heparin, on Mortality, Reinfarction, and Strokes in Patients With Acute Myocardial Infarction Presenting With ST-Segment Elevation. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 427.	3.8	137
278	Environmental and societal influences acting on cardiovascular risk factors and disease at a population level: a review. <i>International Journal of Epidemiology</i> , 2009, 38, 1580-1594.	0.9	137
279	A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE) Tj ETQq1 1 0,784314 rgBT /Ove	6.3	137
280	Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , 2003, 107, 251-257.	1.6	136
281	Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. <i>BMJ, The</i> , 2021, 374, n1554.	3.0	136
282	Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk. <i>Circulation</i> , 2011, 123, 1098-1107.	1.6	135
283	Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. <i>Lancet Public Health, The</i> , 2017, 2, e411-e419.	4.7	134
284	Incidence, Predictive Factors, and Prognostic Significance of Supraventricular Tachyarrhythmias in Congestive Heart Failure. <i>Chest</i> , 2000, 118, 914-922.	0.4	133
285	Variation in Warfarin Dose Adjustment Practice Is Responsible for Differences in the Quality of Anticoagulation Control Between Centers and Countries. <i>Circulation</i> , 2012, 126, 2309-2316.	1.6	133
286	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	0.8	133
287	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. <i>Lancet, The</i> , 2021, 398, 1053-1064.	6.3	133
288	Development of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 641-647.	3.0	130

#	ARTICLE	IF	CITATIONS
289	Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction. <i>Circulation</i> , 2005, 112, 3855-3867.	1.6	130
290	Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). <i>PLoS ONE</i> , 2011, 6, e22112.	1.1	128
291	A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. <i>American Journal of Medicine</i> , 2004, 116, 300-304.	0.6	127
292	Effect of vasodilators on survival in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1985, 55, 1110-1113.	0.7	126
293	Tranexamic Acid in Patients Undergoing Noncardiac Surgery. <i>New England Journal of Medicine</i> , 2022, 386, 1986-1997.	13.9	125
294	Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality. <i>New England Journal of Medicine</i> , 2021, 384, 1312-1322.	13.9	124
295	Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients With Reduced and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 590-595.	1.6	123
296	The World Heart Federation's vision for worldwide cardiovascular disease prevention. <i>Lancet, The</i> , 2015, 386, 399-402.	6.3	123
297	The relationship between estimated sodium and potassium excretion and subsequent renal outcomes. <i>Kidney International</i> , 2014, 86, 1205-1212.	2.6	122
298	Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV1 (PURE): an international, community-based cohort study. <i>The Lancet Global Health</i> , 2019, 7, e613-e623.	2.9	122
299	Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction. <i>Circulation</i> , 2009, 120, 2429-2437.	1.6	121
300	Comprehensive Analysis of Genomic Variation in the <i>LPA</i> Locus and Its Relationship to Plasma Lipoprotein(a) in South Asians, Chinese, and European Caucasians. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 39-46.	5.1	120
301	Toward Fairness in Data Sharing. <i>New England Journal of Medicine</i> , 2016, 375, 405-407.	13.9	120
302	Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. <i>Annals of Internal Medicine</i> , 2011, 155, 579.	2.0	119
303	Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. <i>Lancet, The</i> , 2020, 396, 968-976.	6.3	119
304	Polygenic determinants of severe hypertriglyceridemia. <i>Human Molecular Genetics</i> , 2008, 17, 2894-2899.	1.4	118
305	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
306	Patterns of Alcohol Consumption and Myocardial Infarction Risk. <i>Circulation</i> , 2014, 130, 390-398.	1.6	117

#	ARTICLE	IF	CITATIONS
307	Health Effects of Household Solid Fuel Use: Findings from 11 Countries within the Prospective Urban and Rural Epidemiology Study. <i>Environmental Health Perspectives</i> , 2019, 127, 57003.	2.8	117
308	Dual-Chamber Versus Ventricular Pacing. <i>Circulation</i> , 1996, 94, 578-583.	1.6	117
309	Parental History and Myocardial Infarction Risk Across the World. <i>Journal of the American College of Cardiology</i> , 2011, 57, 619-627.	1.2	116
310	Chronic Pain Syndromes After Ischemic Stroke. <i>Stroke</i> , 2013, 44, 1238-1243.	1.0	116
311	Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 798-808.	5.5	116
312	Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. <i>JAMA Psychiatry</i> , 2020, 77, 1052.	6.0	116
313	INTER-HEART: A global study of risk factors for acute myocardial infarction. <i>American Heart Journal</i> , 2001, 141, 711-721.	1.2	115
314	Development and evaluation of cultural food frequency questionnaires for South Asians, Chinese, and Europeans in North America. <i>Journal of the American Dietetic Association</i> , 2003, 103, 1178-1184.	1.3	115
315	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. <i>European Heart Journal</i> , 2008, 30, 900-907.	1.0	115
316	Secretory Phospholipase A2-IIA and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1966-1976.	1.2	115
317	Cognitive impairment and risk of cardiovascular events and mortality. <i>European Heart Journal</i> , 2012, 33, 1777-1786.	1.0	114
318	Why are we failing to implement effective therapies in cardiovascular disease?. <i>European Heart Journal</i> , 2013, 34, 1262-1269.	1.0	114
319	Clinical characteristics of patients in Studies of Left Ventricular Dysfunction (SOLVD). <i>American Journal of Cardiology</i> , 1992, 70, 894-900.	0.7	113
320	Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. <i>American Heart Journal</i> , 2000, 139, 609-617.	1.2	113
321	Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention. <i>Circulation</i> , 2005, 111, 1390-1397.	1.6	113
322	Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. <i>American Heart Journal</i> , 2013, 166, 636-646.e4.	1.2	113
323	Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction. <i>Circulation</i> , 2016, 134, 1059-1067.	1.6	112
324	The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1189-1194.	0.8	111

#	ARTICLE	IF	CITATIONS
325	Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. <i>European Heart Journal</i> , 2012, 33, 452-466.	1.0	109
326	Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study. <i>International Journal of Cardiology</i> , 2016, 204, 133-141.	0.8	108
327	Long-Term Oral Anticoagulant Therapy in Patients With Unstable Angina or Suspected Non-Q-Wave Myocardial Infarction. <i>Circulation</i> , 1998, 98, 1064-1070.	1.6	107
328	Adherence to medication according to sex and age in the CHARM programme. <i>European Journal of Heart Failure</i> , 2009, 11, 1092-1098.	2.9	107
329	Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: A systematic review and meta analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2013, 165, 17-24.	0.8	106
330	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. <i>European Heart Journal</i> , 2015, 36, 1454-1462.	1.0	106
331	Associations of outdoor fine particulate air pollution and cardiovascular disease in 157 436 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. <i>Lancet Planetary Health</i> , The, 2020, 4, e235-e245.	5.1	106
332	Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. <i>Clinical Trials</i> , 2009, 6, 239-251.	0.7	105
333	Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. <i>Atherosclerosis</i> , 2012, 225, 444-449.	0.4	105
334	Perioperative Aspirin and Clonidine and Risk of Acute Kidney Injury. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2254.	3.8	105
335	Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. <i>Journal of the American College of Cardiology</i> , 2005, 45, 838-845.	1.2	103
336	Effects of Telmisartan, Ramipril, and Their Combination on Left Ventricular Hypertrophy in Individuals at High Vascular Risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. <i>Circulation</i> , 2009, 120, 1380-1389.	1.6	103
337	Randomized Clinical Trials – Removing Unnecessary Obstacles. <i>New England Journal of Medicine</i> , 2013, 369, 1061-1065.	13.9	103
338	Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. <i>American Journal of Human Genetics</i> , 2017, 101, 925-938.	2.6	103
339	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. <i>European Heart Journal</i> , 2020, 41, 3363-3373.	1.0	103
340	Relationship Between Pacemaker Dependency and the Effect of Pacing Mode on Cardiovascular Outcomes. <i>Circulation</i> , 2001, 103, 3081-3085.	1.6	102
341	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. <i>Kidney International</i> , 2004, 65, 1375-1380.	2.6	102
342	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Added trial. <i>American Heart Journal</i> , 2006, 151, 985-991.	1.2	102

#	ARTICLE	IF	CITATIONS
343	Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. <i>European Heart Journal</i> , 2012, 33, 2804-2812.	1.0	102
344	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , 2021, 143, 2129-2142.	1.6	101
345	Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. <i>American Journal of Cardiology</i> , 1995, 75, 1151-1157.	0.7	100
346	Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus. <i>JAMA Internal Medicine</i> , 2013, 173, 1682-92.	2.6	100
347	Preoperative <i>N</i> -Terminal Pro-B-Type Natriuretic Peptide and Cardiovascular Events After Noncardiac Surgery. <i>Annals of Internal Medicine</i> , 2020, 172, 96.	2.0	99
348	Antithrombotic Therapy With Fondaparinux in Relation to Interventional Management Strategy in Patients With ST- and Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2008, 118, 2038-2046.	1.6	98
349	Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin. <i>Circulation</i> , 2003, 107, 2884-2888.	1.6	97
350	Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. <i>American Heart Journal</i> , 2007, 154, 448-453.	1.2	97
351	Primary Prevention With Statin Therapy in the Elderly. <i>Circulation</i> , 2017, 135, 1979-1981.	1.6	97
352	Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 277-283.	0.9	96
353	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. <i>Lancet</i> , 2018, 391, 2019-2027.	6.3	96
354	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
355	Left Atrial Appendage Occlusion Study II (LAAOS II). <i>Canadian Journal of Cardiology</i> , 2013, 29, 1443-1447.	0.8	95
356	Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. <i>European Heart Journal</i> , 2015, 36, 2364-2372.	1.0	95
357	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3271-3280.	1.2	95
358	Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 1468-1480.	1.6	95
359	Prognostic value of prolonged ventricular repolarization following myocardial infarction: The BHAT experience. <i>Journal of Clinical Epidemiology</i> , 1990, 43, 167-172.	2.4	94
360	Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: A critical analysis based on 100 studies. <i>Progress in Cardiovascular Diseases</i> , 2000, 43, 171-196.	1.6	94



#	ARTICLE	IF	CITATIONS
361	Resequencing Genomic DNA of Patients With Severe Hypertriglyceridemia (MIM 144650). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2450-2455.	1.1	94
362	Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2012, 21, 429-435.	0.7	94
363	Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2200-2206.	1.2	93
364	Calcium Antagonists in Coronary Artery Disease and Hypertension. <i>Circulation</i> , 1995, 92, 1079-1082.	1.6	93
365	Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 244-253.	5.5	92
366	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	1.0	92
367	Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. <i>American Heart Journal</i> , 2010, 160, 1178-1184.	1.2	91
368	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , 2016, 45, 77-83.	0.7	91
369	Impact of Sex on Cardiovascular Outcome in Patients at High Cardiovascular Risk. <i>Circulation</i> , 2012, 126, 934-941.	1.6	90
370	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2015, 132, 796-803.	1.6	90
371	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , 2020, 41, 4037-4046.	1.0	90
372	The household economic burden of non-communicable diseases in 18 countries. <i>BMJ Global Health</i> , 2020, 5, e002040.	2.0	90
373	Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. <i>Journal of the American College of Cardiology</i> , 1999, 33, 612-619.	1.2	88
374	A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. <i>Human Molecular Genetics</i> , 2009, 18, 4189-4194.	1.4	88
375	Household and personal air pollution exposure measurements from 120 communities in eight countries: results from the PURE-AIR study. <i>Lancet Planetary Health</i> , The, 2020, 4, e451-e462.	5.1	88
376	Elevated lipoprotein(a) levels in South Asians in North America. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 182-184.	1.5	87
377	Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery. <i>Annals of Internal Medicine</i> , 2018, 168, 237.	2.0	87
378	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. <i>Lancet</i> , The, 2021, 398, 1133-1146.	6.3	87



#	ARTICLE	IF	CITATIONS
379	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. <i>Kidney International</i> , 2015, 87, 784-791.	2.6	86
380	Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non- $\sigma$ ST-Segment Elevation Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2007, 147, 304.	2.0	85
381	Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2019, 364, 1772.	2.4	85
382	Carbohydrate intake and HDL in a multiethnic population. <i>American Journal of Clinical Nutrition</i> , 2007, 85, 225-230.	2.2	84
383	An Increased Burden of Common and Rare Lipid-Associated Risk Alleles Contributes to the Phenotypic Spectrum of Hypertriglyceridemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 1916-1926.	1.1	84
384	Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1845-1854.	1.2	84
385	Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin. <i>Stroke</i> , 2012, 43, 3291-3297.	1.0	83
386	Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial. <i>International Journal of Cardiology</i> , 2014, 174, 458-461.	0.8	83
387	The COMPASS Trial. <i>Circulation</i> , 2020, 142, 40-48.	1.6	83
388	Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation. <i>Circulation</i> , 2007, 116, 449-455.	1.6	82
389	Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 645-653.	0.4	82
390	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1053-1061.	2.9	82
391	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. <i>European Heart Journal</i> , 2010, 31, 50-58.	1.0	81
392	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 529-537.	1.6	81
393	Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk. <i>Hypertension</i> , 2015, 65, 651-661.	1.3	80
394	Excess of Rare Variants in Non- $\sigma$ Genome-Wide Association Study Candidate Genes in Patients With Hypertriglyceridemia. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 66-72.	5.1	79
395	Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 400-410.	0.8	79
396	Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: The need for randomized trials. <i>American Journal of Cardiology</i> , 1992, 69, 959-962.	0.7	78

#	ARTICLE	IF	CITATIONS
397	Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. <i>American Heart Journal</i> , 2007, 154, 743-750.	1.2	78
398	High-Sensitivity Cardiac Troponin I Measurement for Risk Stratification in a Stable High-Risk Population. <i>Clinical Chemistry</i> , 2011, 57, 1146-1153.	1.5	78
399	Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. <i>Circulation</i> , 2016, 133, 742-755.	1.6	78
400	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , 2017, 103, 1015-1023.	1.2	78
401	The Effect of Chromosome 9p21 Variants on Cardiovascular Disease May Be Modified by Dietary Intake: Evidence from a Case/Control and a Prospective Study. <i>PLoS Medicine</i> , 2011, 8, e1001106.	3.9	76
402	The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. <i>Diabetes Care</i> , 2014, 37, 1360-1366.	4.3	76
403	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 1697-1707.	1.6	76
404	Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. <i>American Journal of Kidney Diseases</i> , 2003, 42, 936-942.	2.1	75
405	Tackling the challenge of cardiovascular disease burden in developing countries. <i>American Heart Journal</i> , 2004, 148, 1-4.	1.2	75
406	Social disadvantage and cardiovascular disease: development of an index and analysis of age, sex, and ethnicity effects. <i>International Journal of Epidemiology</i> , 2006, 35, 1239-1245.	0.9	75
407	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation</i> , 2015, 131, 43-53.	1.6	75
408	Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. <i>Lancet</i> , The, 2000, 356, 449-454.	6.3	74
409	Estimated Glomerular Filtration Rate and Albuminuria as Predictors of Outcomes in Patients With High Cardiovascular Risk. <i>Annals of Internal Medicine</i> , 2011, 154, 310.	2.0	74
410	Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. <i>European Heart Journal</i> , 2011, 32, 2135-2142.	1.0	74
411	Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. <i>International Journal of Cardiology</i> , 2015, 196, 127-131.	0.8	74
412	Alteplase for Acute Ischemic Stroke. <i>Stroke</i> , 2015, 46, 746-756.	1.0	74
413	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2006, 152, 86-92.	1.2	74
414	Effect of Telmisartan on Functional Outcome, Recurrence, and Blood Pressure in Patients With Acute Mild Ischemic Stroke. <i>Stroke</i> , 2009, 40, 3541-3546.	1.0	73

#	ARTICLE	IF	CITATIONS
415	Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. <i>European Heart Journal</i> , 2014, 35, 353-364.	1.0	73
416	Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. <i>The Lancet Global Health</i> , 2018, 6, e292-e301.	2.9	73
417	A Family-based Intervention to Promote Healthy Lifestyles in an Aboriginal Community in Canada. <i>Canadian Journal of Public Health</i> , 2007, 98, 447-452.	1.1	72
418	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , 2018, 39, 750-757a.	1.0	72
419	Patients' Knowledge, Attitudes, Behaviour and Health Care Experiences on the Prevention, Detection, Management and Control of Hypertension in Colombia: A Qualitative Study. <i>PLoS ONE</i> , 2015, 10, e0122112.	1.1	71
420	Interpreting Geographic Variations in Results of Randomized, Controlled Trials. <i>New England Journal of Medicine</i> , 2016, 375, 2263-2271.	13.9	71
421	Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 795-803.	2.2	71
422	Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic Population. <i>Diabetes Care</i> , 2003, 26, 290-296.	4.3	70
423	Environmental Profile of a Community's Health (EPOCH): An Instrument to Measure Environmental Determinants of Cardiovascular Health in Five Countries. <i>PLoS ONE</i> , 2010, 5, e14294.	1.1	70
424	Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 463-471.	0.9	70
425	Procedural Volume and Outcomes With Radial or Femoral Access for Coronary Angiography and Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 954-963.	1.2	70
426	Systolic and Diastolic Blood Pressure Changes in Relation With Myocardial Infarction and Stroke in Patients With Coronary Artery Disease. <i>Hypertension</i> , 2015, 65, 108-114.	1.3	70
427	Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 300-310.	1.2	69
428	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. <i>Journal of the American College of Cardiology</i> , 2019, 73, 121-130.	1.2	69
429	High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality. <i>New England Journal of Medicine</i> , 2022, 386, 827-836.	13.9	69
430	Global differences in lung function by region (PURE): an international, community-based prospective study. <i>Lancet Respiratory Medicine</i> , 2013, 1, 599-609.	5.2	68
431	Diet and Major Renal Outcomes: A Prospective Cohort Study. <i>The NIH-AARP Diet and Health Study</i> , 2016, 26, 288-298.		68
432	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. <i>JAMA Internal Medicine</i> , 2021, 181, 631.	2.6	68

#	ARTICLE	IF	CITATIONS
433	Usefulness of Temporal Changes in Neurohormones as Markers of Ventricular Remodeling and Prognosis in Patients With Left Ventricular Systolic Dysfunction and Heart Failure Receiving Either Candesartan or Enalapril or Both. <i>American Journal of Cardiology</i> , 2005, 96, 698-704.	0.7	67
434	Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: Further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. <i>American Heart Journal</i> , 2005, 150, 1177-1184.	1.2	67
435	Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. <i>American Heart Journal</i> , 2006, 151, 219-227.	1.2	67
436	Genetic Variants Associated With Myocardial Infarction Risk Factors in Over 8000 Individuals From Five Ethnic Groups. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 16-25.	5.1	67
437	Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Treated With Glycoprotein IIb/IIIa Inhibitors or Thienopyridines. <i>Journal of the American College of Cardiology</i> , 2009, 54, 468-476.	1.2	67
438	Rationale and design of The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study: A large international randomized trial in cardiac surgery. <i>American Heart Journal</i> , 2012, 163, 1-6.	1.2	67
439	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. <i>PLoS Medicine</i> , 2018, 15, e1002538.	3.9	67
440	Relationship of Anti-60 kDa Heat Shock Protein and Anti-Cholesterol Antibodies to Cardiovascular Events. <i>Circulation</i> , 2002, 106, 2775-2780.	1.6	66
441	Impact of Candesartan on Nonfatal Myocardial Infarction and Cardiovascular Death in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 1794.	3.8	66
442	Design and rationale of the TOTAL trial: A randomized trial of routine aspiration Thrombectomy with percutaneous coronary intervention (PCI) versus PCI Alone in patients with ST-elevation myocardial infarction undergoing primary PCI. <i>American Heart Journal</i> , 2014, 167, 315-321.e1.	1.2	66
443	Sodium Intake and Renal Outcomes: A Systematic Review. <i>American Journal of Hypertension</i> , 2014, 27, 1277-1284.	1.0	66
444	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. <i>European Journal of Heart Failure</i> , 2018, 20, 295-303.	2.9	65
445	Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2012, 59, 854-855.	1.2	64
446	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. <i>Circulation</i> , 2015, 132, 2297-2304.	1.6	64
447	Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction. <i>Circulation</i> , 2004, 110, 1413-1417.	1.6	63
448	Meta-Analysis of the INSIG2 Association with Obesity Including 74,345 Individuals: Does Heterogeneity of Estimates Relate to Study Design?. <i>PLoS Genetics</i> , 2009, 5, e1000694.	1.5	62
449	Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. <i>European Heart Journal</i> , 2012, 33, 51-60.	1.0	62
450	Healthy eating and reduced risk of cognitive decline. <i>Neurology</i> , 2015, 84, 2258-2265.	1.5	62

#	ARTICLE	IF	CITATIONS
451	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015, 36, 669-675.	1.0	62
452	Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. <i>Scientific Reports</i> , 2016, 6, 18672.	1.6	62
453	Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: Substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). <i>American Heart Journal</i> , 2007, 154, 94-101.	1.2	61
454	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Diabetes Care</i> , 2009, 32, 915-920.	4.3	61
455	Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. <i>American Heart Journal</i> , 1982, 103, 459-467.	1.2	60
456	Characterizing exposure to household air pollution within the Prospective Urban Rural Epidemiology (PURE) study. <i>Environment International</i> , 2018, 114, 307-317.	4.8	60
457	Correction of Population Stratification in Large Multi-Ethnic Association Studies. <i>PLoS ONE</i> , 2008, 3, e1382.	1.1	60
458	Role of Magnesium in Reducing Mortality in Acute Myocardial Infarction. <i>Drugs</i> , 1993, 46, 347-359.	4.9	59
459	Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , 2003, 107, 960-965.	1.6	59
460	Interrelation of saturated fat, trans fat, alcohol intake, and subclinical atherosclerosis. <i>American Journal of Clinical Nutrition</i> , 2008, 87, 168-174.	2.2	59
461	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , 2010, 12, 557-565.	2.9	59
462	Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 62, 900-908.	1.2	59
463	Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. <i>Kidney International</i> , 2017, 91, 683-690.	2.6	59
464	Stroke in Relation to Cardiac Procedures in Patients With Non-ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 2001, 104, 269-274.	1.6	58
465	Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population. <i>PLoS ONE</i> , 2013, 8, e66808.	1.1	57
466	Association of dairy consumption with metabolic syndrome, hypertension and diabetes in 147%812 individuals from 21 countries. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000826.	1.2	57
467	Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. <i>Atherosclerosis</i> , 2004, 176, 361-370.	0.4	56
468	The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. <i>European Heart Journal</i> , 2008, 29, 324-331.	1.0	56

#	ARTICLE	IF	CITATIONS
469	Association of Household Wealth Index, Educational Status, and Social Capital with Hypertension Awareness, Treatment, and Control in South Asia. <i>American Journal of Hypertension</i> , 2017, 30, 373-381.	1.0	56
470	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 255-267.	1.2	56
471	Prevalence, awareness, treatment and control of hypertension in rural and urban communities in Latin American countries. <i>Journal of Hypertension</i> , 2019, 37, 1813-1821.	0.3	56
472	Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154,000 Individuals. <i>Journal of the American Heart Association</i> , 2020, 9, e014686.	1.6	56
473	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 545-549.	1.3	55
474	White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries. <i>Diabetes Care</i> , 2020, 43, 2643-2650.	4.3	55
475	APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 730-737.	3.3	54
476	Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. <i>Journal of Lipid Research</i> , 2009, 50, 1487-1496.	2.0	54
477	Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2028-2035.	1.2	54
478	Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). <i>Hypertension</i> , 2012, 60, 1400-1406.	1.3	54
479	Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 1261-1271.	0.8	54
480	Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2015, 116, 1204-1209.	0.7	54
481	Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the <sc>CHARM</sc> study programme. <i>European Journal of Heart Failure</i> , 2016, 18, 1508-1517.	2.9	54
482	Effects of blood pressure and lipid lowering on cognition. <i>Neurology</i> , 2019, 92, e1435-e1446.	1.5	54
483	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes. <i>JAMA Neurology</i> , 2020, 77, 43.	4.5	54
484	Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. <i>Indian Heart Journal</i> , 2005, 57, 217-25.	0.2	54
485	Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. <i>Human Molecular Genetics</i> , 2015, 24, 3582-3594.	1.4	53
486	Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study. <i>BMJ</i> , The, 2021, 372, m4948.	3.0	53



#	ARTICLE	IF	CITATIONS
487	Effect of long-term therapy with ramipril in high-risk women. <i>Journal of the American College of Cardiology</i> , 2002, 40, 693-702.	1.2	52
488	Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. <i>European Heart Journal</i> , 2003, 24, 1727-1734.	1.0	52
489	Influenza Vaccination and Major Adverse Vascular Events in High-Risk Patients. <i>Circulation</i> , 2012, 126, 278-286.	1.6	52
490	Predictors of early and late stroke following cardiac surgery. <i>Cmaj</i> , 2014, 186, 905-911.	0.9	52
491	Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 562-572.	5.5	52
492	Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. <i>American Heart Journal</i> , 2016, 178, 145-150.	1.2	52
493	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 504-510.	2.9	52
494	Obtaining medically meaningful answers from an overview of randomized clinical trials. <i>Statistics in Medicine</i> , 1987, 6, 281-286.	0.8	51
495	Studies of left ventricular dysfunction (SOLVD) registry: Rationale, design, methods and description of baseline characteristics. <i>American Journal of Cardiology</i> , 1992, 70, 347-353.	0.7	51
496	The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina. <i>American Journal of Cardiology</i> , 1999, 84, 7-12.	0.7	51
497	Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. <i>Current Cardiology Reports</i> , 2000, 2, 293-299.	1.3	51
498	The Relationship Between Dysglycemia and Atherosclerosis in South Asian, Chinese, and European Individuals in Canada: A randomly sampled cross-sectional study. <i>Diabetes Care</i> , 2003, 26, 144-149.	4.3	51
499	Sensible guidelines for the conduct of large randomized trials. <i>Clinical Trials</i> , 2008, 5, 38-39.	0.7	51
500	Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia. <i>Atherosclerosis</i> , 2013, 229, 234-239.	0.4	51
501	Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries. <i>Circulation</i> , 2020, 141, 2004-2025.	1.6	51
502	Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction. <i>American Journal of Cardiology</i> , 1987, 59, 245-250.	0.7	50
503	Effect of Rosiglitazone and Ramipril on $\beta$ -Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: The DREAM trial. <i>Diabetes Care</i> , 2010, 33, 608-613.	4.3	50
504	Effect of drug therapy on survival in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1988, 62, 41A-45A.	0.7	49



#	ARTICLE	IF	CITATIONS
505	Dysglycaemia and risk of cardiovascular disease. <i>Lancet, The</i> , 1996, 347, 1833-1835.	6.3	49
506	Protein Intake Is Inversely Associated with Abdominal Obesity in a Multi-Ethnic Population. <i>Journal of Nutrition</i> , 2005, 135, 1196-1201.	1.3	49
507	Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. <i>Heart</i> , 2018, 104, 581-587.	1.2	49
508	Evaluating effects of treatment in subgroups of patients within a clinical trial: The case of non-Q-wave myocardial infarction and beta blockers. <i>American Journal of Cardiology</i> , 1990, 66, 220-222.	0.7	48
509	Lipid lowering for primary prevention. <i>Lancet, The</i> , 2009, 373, 1152-1155.	6.3	48
510	Peripheral Blood <i>&lt;i&gt;MCEMP1&lt;/i&gt;</i> Gene Expression as a Biomarker for Stroke Prognosis. <i>Stroke</i> , 2016, 47, 652-658.	1.0	48
511	Digoxinâ€™ mortality: randomized vs. observational comparison in the DIG trial. <i>European Heart Journal</i> , 2019, 40, 3336-3341.	1.0	48
512	Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery. <i>European Heart Journal</i> , 2020, 41, 645-651.	1.0	48
513	Patterns of Medication Use in Patients With Heart Failure. <i>Southern Medical Journal</i> , 1995, 88, 514-523.	0.3	47
514	Prevalence and prognostic impact of bundle branch block in patients with heart failure: Evidence from the CHARM programme. <i>European Journal of Heart Failure</i> , 2007, 9, 510-517.	2.9	47
515	The Family Atherosclerosis Monitoring In earLY life (FAMILY) study. <i>American Heart Journal</i> , 2009, 158, 533-539.	1.2	47
516	C-reactive protein is a bystander of cardiovascular disease. <i>European Heart Journal</i> , 2010, 31, 2092-2096.	1.0	47
517	Effect of Combined Aspirin and Extended-Release Dipyridamole Versus Clopidogrel on Functional Outcome and Recurrence in Acute, Mild Ischemic Stroke. <i>Stroke</i> , 2010, 41, 732-738.	1.0	47
518	Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?. <i>European Heart Journal</i> , 2013, 34, 1630-1635.	1.0	47
519	Additional Events in the RE-LY Trial. <i>New England Journal of Medicine</i> , 2014, 371, 1464-1465.	13.9	47
520	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. <i>Diabetologia</i> , 2014, 57, 1325-1331.	2.9	47
521	Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 682-690.	2.4	47
522	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019, 40, 2032-2043.	1.0	47

#	ARTICLE	IF	CITATIONS
523	Long-term exposure to outdoor and household air pollution and blood pressure in the Prospective Urban and Rural Epidemiological (PURE) study. <i>Environmental Pollution</i> , 2020, 262, 114197.	3.7	47
524	Cost of Prevention. <i>Circulation</i> , 1996, 93, 1774-1776.	1.6	47
525	Development of food frequency questionnaires and a nutrient database for the Prospective Urban and Rural Epidemiological (PURE) pilot study in South India: methodological issues. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2008, 17, 178-85.	0.3	47
526	Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. <i>Clinical Trials</i> , 2007, 4, 218-234.	0.7	46
527	Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and) Tj ETQq1 1 0.784314 rgBT /Overlo 2009, 104, 1484-1489.	0.7	46
528	Relationship Between Degree of Left Ventricular Dysfunction, Symptom Status, and Risk of Embolic Events in Patients With Atrial Fibrillation and Heart Failure. <i>Stroke</i> , 2015, 46, 667-672.	1.0	46
529	Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study. <i>American Journal of Kidney Diseases</i> , 2016, 68, 29-40.	2.1	46
530	Associations of unprocessed and processed meat intake with mortality and cardiovascular disease in 21 countries [Prospective Urban Rural Epidemiology (PURE) Study]: a prospective cohort study. <i>American Journal of Clinical Nutrition</i> , 2021, 114, 1049-1058.	2.2	46
531	Tolerability of enalapril initiation by patients with left ventricular dysfunction: Results of the medication challenge phase of the studies of left ventricular dysfunction. <i>American Heart Journal</i> , 1994, 128, 358-364.	1.2	45
532	Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. <i>American Journal of Cardiology</i> , 1995, 75, 1244-1249.	0.7	44
533	Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. <i>Clinical Biochemistry</i> , 2013, 46, 5-9.	0.8	44
534	Tobacco control environment: cross-sectional survey of policy implementation, social unacceptability, knowledge of tobacco health harms and relationship to quit ratio in 17 low-income, middle-income and high-income countries. <i>BMJ Open</i> , 2017, 7, e013817.	0.8	44
535	The Evolution of $\beta$ -Blockers in Coronary Artery Disease and Heart Failure (Part 1/5). <i>Journal of the American College of Cardiology</i> , 2019, 74, 672-682.	1.2	44
536	Prognostic Significance of Thrombocytopenia During Hirudin and Heparin Therapy in Acute Coronary Syndrome Without ST Elevation. <i>Circulation</i> , 2001, 103, 643-650.	1.6	43
537	Effect of candesartan on New York Heart Association functional class Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2004, 25, 1920-1926.	1.0	43
538	Sodium and Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2014, 371, 2134-2139.	13.9	43
539	Influence of Hospitalization for Cardiovascular Versus Noncardiovascular Reasons on Subsequent Mortality in Patients With Chronic Heart Failure Across the Spectrum of Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 895-902.	1.6	43
540	The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. <i>American Heart Journal</i> , 2020, 225, 69-77.	1.2	43

#	ARTICLE	IF	CITATIONS
541	The 24-hour heart rate behavior in long-term survivors of cardiac transplantation. <i>American Journal of Cardiology</i> , 1988, 61, 880-884.	0.7	42
542	Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: The CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. <i>American Heart Journal</i> , 2004, 148, 1068-1078.	1.2	42
543	Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2000-2007.	1.2	42
544	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , 2014, 35, 2242-2248.	1.0	42
545	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , 2017, 190, 94-103.	1.2	42
546	Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy. <i>European Heart Journal</i> , 2022, 43, 2852-2863.	1.0	42
547	Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy. <i>European Heart Journal</i> , 2022, 43, 2831-2840.	1.0	42
548	Are we biased in our approach to treating elderly patients with heart disease?. <i>American Journal of Cardiology</i> , 1991, 68, 954-956.	0.7	41
549	Social disparities explain differences in hypertension prevalence, detection and control in Colombia. <i>Journal of Hypertension</i> , 2016, 34, 2344-2352.	0.3	41
550	Evaluation of Adiposity and Cognitive Function in Adults. <i>JAMA Network Open</i> , 2022, 5, e2146324.	2.8	41
551	Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity programme. <i>European Heart Journal</i> , 2008, 29, 3022-3028.	1.0	40
552	Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events. <i>Diabetes Care</i> , 2013, 36, 2466-2474.	4.3	40
553	Central statistical monitoring: Detecting fraud in clinical trials. <i>Clinical Trials</i> , 2013, 10, 225-235.	0.7	40
554	Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. <i>Diabetologia</i> , 2014, 57, 2019-2029.	2.9	40
555	Dietary Saturated Fats and Health: Are the U.S. Guidelines Evidence-Based?. <i>Nutrients</i> , 2021, 13, 3305.	1.7	40
556	Designing and Analyzing Clinical Trials with Composite Outcomes: Consideration of Possible Treatment Differences between the Individual Outcomes. <i>PLoS ONE</i> , 2012, 7, e34785.	1.1	40
557	Gene-Centric Meta-Analysis of Lipid Traits in African, East Asian and Hispanic Populations. <i>PLoS ONE</i> , 2012, 7, e50198.	1.1	40
558	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2243-2250.	1.2	39

#	ARTICLE	IF	CITATIONS
559	Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design. <i>American Heart Journal</i> , 2019, 212, 36-44.	1.2	39
560	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
561	Sodium Intake and Health: What Should We Recommend Based on the Current Evidence?. <i>Nutrients</i> , 2021, 13, 3232.	1.7	39
562	Maternal and Pregnancy Related Predictors of Cardiometabolic Traits in Newborns. <i>PLoS ONE</i> , 2013, 8, e55815.	1.1	38
563	Prevalence of mitral valve prolapse in ethnic groups. <i>Canadian Journal of Cardiology</i> , 2004, 20, 511-5.	0.8	38
564	Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. <i>European Heart Journal</i> , 2008, 29, 315-323.	1.0	37
565	Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada. <i>Atherosclerosis</i> , 2009, 203, 192-200.	0.4	37
566	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , 2012, 129, 715-719.	0.8	37
567	Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 468-477.	0.8	37
568	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020, 9, e018984.	1.6	37
569	Psychosocial Risk Factors and Cardiovascular Disease and Death in a Population-Based Cohort From 21 Low-, Middle-, and High-Income Countries. <i>JAMA Network Open</i> , 2021, 4, e2138920.	2.8	37
570	A Lifetime of Prevention. <i>Circulation</i> , 2002, 106, 2997-2998.	1.6	36
571	The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 299-309.	0.8	36
572	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , 2017, 38, ehw509.	1.0	36
573	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
574	Tackling NCD in LMIC: Achievements and Lessons Learned From the NHLBI's UnitedHealth Global Health Centers of Excellence Program. <i>Global Heart</i> , 2016, 11, 5.	0.9	36
575	Choice of clinical outcomes in randomized trials of heart failure therapies: Disease-specific or overall outcomes?. <i>American Heart Journal</i> , 2002, 143, 22-28.	1.2	35
576	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2005, 27, 1447-1458.	1.0	35

#	ARTICLE	IF	CITATIONS
577	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010, 31, 2133-2140.	1.0	35
578	Marital Status, Education, and Risk of Acute Myocardial Infarction in Mainland China: The INTER-HEART Study. <i>Journal of Epidemiology</i> , 2012, 22, 123-129.	1.1	35
579	Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study. <i>Anesthesia and Analgesia</i> , 2017, 125, 162-169.	1.1	35
580	Secondary CV Prevention in South America in a Community Setting: The PURE Study. <i>Global Heart</i> , 2017, 12, 305.	0.9	35
581	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020, 41, 231-238.	1.0	35
582	Effects of calcium channel blockers on survival after myocardial infarction. <i>Cardiovascular Drugs and Therapy</i> , 1987, 1, 343-344.	1.3	34
583	Variation at the <i>NFATC2</i> Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. <i>Diabetes Care</i> , 2010, 33, 2250-2253.	4.3	34
584	Challenges in management and prevention of ischemic heart disease in low socioeconomic status people in LLMICs. <i>BMC Medicine</i> , 2019, 17, 209.	2.3	34
585	Classifying ethnicity utilizing the Canadian mortality data base. <i>Ethnicity and Health</i> , 1997, 2, 287-295.	1.5	33
586	Racial differences in outcome and treatment effect in congestive heart failure. <i>American Heart Journal</i> , 2005, 150, 968-976.	1.2	33
587	Nutrition labelling, marketing techniques, nutrition claims and health claims on chip and biscuit packages from sixteen countries. <i>Public Health Nutrition</i> , 2016, 19, 998-1007.	1.1	33
588	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2021, 6, 21-29.	3.0	33
589	Association of nut intake with risk factors, cardiovascular disease, and mortality in 16 countries from 5 continents: analysis from the Prospective Urban and Rural Epidemiology (PURE) study. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 208-219.	2.2	33
590	Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153%152 middle-aged individuals. <i>Cardiovascular Research</i> , 2021, 117, 1523-1531.	1.8	33
591	Multi-Ethnic Genetic Association Study of Carotid Intima-Media Thickness Using a Targeted Cardiovascular SNP Microarray. <i>Stroke</i> , 2009, 40, 3173-3179.	1.0	32
592	The Mini-Mental State Examination, Clinical Factors, and Motor Vehicle Crash Risk. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 1419-1426.	1.3	32
593	Patient and System-Related Delays of Emergency Medical Services Use in Acute ST-Elevation Myocardial Infarction: Results from the Third Gulf Registry of Acute Coronary Events (Gulf RACE-3Ps). <i>PLoS ONE</i> , 2016, 11, e0147385.	1.1	32
594	Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. <i>Diabetes Care</i> , 2020, 43, 3094-3101.	4.3	32

#	ARTICLE	IF	CITATIONS
595	Diurnal variations of QT interval after cardiac transplantation. <i>American Journal of Cardiology</i> , 1988, 61, 482-485.	0.7	31
596	Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. <i>European Heart Journal</i> , 2007, 28, 1382-1388.	1.0	31
597	Capacity planning for cardiac catheterization: A case study. <i>Health Policy</i> , 2007, 82, 1-11.	1.4	31
598	Polypills. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1368-1370.	1.2	31
599	Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iv76-iv85.	0.4	31
600	Effects of bidi smoking on all-cause mortality and cardiorespiratory outcomes in men from south Asia: an observational community-based substudy of the Prospective Urban Rural Epidemiology Study (PURE). <i>The Lancet Global Health</i> , 2017, 5, e168-e176.	2.9	31
601	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. <i>Hypertension</i> , 2017, 70, 938-948.	1.3	31
602	Effect of Body Mass Index on Clinical Events After Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2017, 120, 1453-1459.	0.7	31
603	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , 2017, 01, e139-e145.	0.7	31
604	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , 2021, 117, 576-584.	1.8	31
605	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 78, 14-23.	1.2	31
606	Effectiveness of preload reserve as a determinant of clinical status in patients with left ventricular systolic dysfunction. <i>American Journal of Cardiology</i> , 1992, 69, 1591-1595.	0.7	30
607	Meta-analysis of randomized trials: Looking back and looking ahead. <i>Contemporary Clinical Trials</i> , 1997, 18, 594-601.	2.0	30
608	Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). <i>Vascular Medicine</i> , 2008, 13, 245-253.	0.8	30
609	Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. <i>European Journal of Heart Failure</i> . 2008. 10. 157-163.	2.9	30
610	Tackling the global burden of stroke: the need for large-scale international studies. <i>Lancet Neurology</i> , The, 2009, 8, 306-307.	4.9	30
611	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. <i>Circulation</i> , 2018, 137, 88-90.	1.6	30
612	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1519-1528.	1.2	30



#	ARTICLE	IF	CITATIONS
613	World Heart Federation Cholesterol Roadmap. <i>Global Heart</i> , 2017, 12, 179.	0.9	30
614	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2141328.	2.8	30
615	Risk factors, cardiovascular disease, and mortality in South America: a PURE substudy. <i>European Heart Journal</i> , 2022, 43, 2841-2851.	1.0	30
616	Association of Sitting Time With Mortality and Cardiovascular Events in High-Income, Middle-Income, and Low-Income Countries. <i>JAMA Cardiology</i> , 2022, 7, 796.	3.0	30
617	Functional capacity in patients with congestive heart failure. <i>Journal of Cardiac Failure</i> , 2000, 6, 214-219.	0.7	29
618	Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2001, 285, 444.	3.8	29
619	Cardiovascular Risk in Patients with Early Renal Insufficiency. <i>American Journal of Cardiovascular Drugs</i> , 2002, 2, 157-162.	1.0	29
620	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , 2016, 139, 77-81.	0.8	29
621	The environmental profile of a community's health: a cross-sectional study on tobacco marketing in 16 countries. <i>Bulletin of the World Health Organization</i> , 2015, 93, 851-861G.	1.5	29
622	Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. <i>American Heart Journal</i> , 1997, 134, 37-43.	1.2	28
623	Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: Outcomes and treatment effect across different levels of risk. <i>American Heart Journal</i> , 2009, 157, 502-508.	1.2	28
624	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. <i>American Heart Journal</i> , 2009, 157, 763-770.	1.2	28
625	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , 2014, 35, 1856-1863.	1.0	28
626	Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations. <i>Human Molecular Genetics</i> , 2014, 23, 2498-2510.	1.4	28
627	Assessing global risk factors for non-fatal injuries from road traffic accidents and falls in adults aged 35-70 years in 17 countries: a cross-sectional analysis of the Prospective Urban Rural Epidemiological (PURE) study. <i>Injury Prevention</i> , 2016, 22, 92-98.	1.2	28
628	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 296-307.	0.8	28
629	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes Care</i> , 2020, 43, 835-842.	4.3	28
630	The relevance of subgroup-specific treatment effects: The Studies Of Left Ventricular Dysfunction (SOLVD) revisited. <i>American Heart Journal</i> , 2002, 144, 941-947.	1.2	27



#	ARTICLE	IF	CITATIONS
631	Effects of Telmisartan on Glucose Levels in People at High Risk for Cardiovascular Disease but Free From Diabetes. <i>Diabetes Care</i> , 2011, 34, 1902-1907.	4.3	27
632	Household, community, sub-national and country-level predictors of primary cooking fuel switching in nine countries from the PURE study. <i>Environmental Research Letters</i> , 2019, 14, 085006.	2.2	27
633	Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. <i>European Heart Journal</i> , 2008, 30, 338-345.	1.0	26
634	Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme. <i>Diabetes Research and Clinical Practice</i> , 2009, 83, 387-393.	1.1	26
635	The functional variant rs1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population. <i>Atherosclerosis</i> , 2009, 206, 199-203.	0.4	26
636	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. <i>European Journal of Heart Failure</i> , 2016, 18, 1162-1171.	2.9	26
637	Association of Urinary Sodium Excretion With Blood Pressure and Cardiovascular Clinical Events in 17,033 Latin Americans. <i>American Journal of Hypertension</i> , 2016, 29, 796-805.	1.0	26
638	Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>American Journal of Kidney Diseases</i> , 2006, 48, 889-896.	2.1	25
639	The Inflammatory Hypothesis. <i>Circulation</i> , 2006, 114, 1557-1560.	1.6	25
640	Effect of PON1 Q192R Genetic Polymorphism on Clopidogrel Efficacy and Cardiovascular Events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events Trial and the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 250-256.	5.1	25
641	Assessment of Dietary Sodium and Potassium in Canadians Using 24-Hour Urinary Collection. <i>Canadian Journal of Cardiology</i> , 2016, 32, 319-326.	0.8	25
642	Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). <i>Canadian Journal of Cardiology</i> , 2018, 34, 295-302.	0.8	25
643	Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005795.	1.4	25
644	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020, 41, 2848-2859.	1.0	25
645	Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level. <i>Heart</i> , 2021, 107, 282-289.	1.2	25
646	The role of serum myoglobin in the detection and measurement of myocardial infarction. <i>Clinica Chimica Acta</i> , 1980, 106, 17-28.	0.5	24
647	Patient perception of the effect of treatment with candesartan in heart failure. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2005, 7, 650-656.	2.9	24
648	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , 2005, 26, 2396-2403.	1.0	24

#	ARTICLE	IF	CITATIONS
649	Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction-a meta-analysis. <i>European Journal of Heart Failure</i> , 2006, 8, 90-96.	2.9	24
650	Preventing Vascular Events Due to Elevated Blood Pressure. <i>Circulation</i> , 2006, 113, 2166-2168.	1.6	24
651	Incidental Magnetic Resonance Diffusion-Weighted Imagingâ€œPositive Lesions Are Rare in Neurologically Asymptomatic Community-Dwelling Adults. <i>Stroke</i> , 2014, 45, 2115-2117.	1.0	24
652	Rationale and design of the Steroids in Cardiac Surgery trial. <i>American Heart Journal</i> , 2014, 167, 660-665.	1.2	24
653	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , 2016, 32, 311-318.	0.8	24
654	The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. <i>American Heart Journal</i> , 2018, 206, 72-79.	1.2	24
655	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , 2020, 227, 56-63.	1.2	24
656	Timing and Length of Nocturnal Sleep and Daytime Napping and Associations With Obesity Types in High-, Middle-, and Low-Income Countries. <i>JAMA Network Open</i> , 2021, 4, e2113775.	2.8	24
657	Fruit, vegetable, and legume intake and the risk of all-cause, cardiovascular, and cancer mortality: A prospective study. <i>Clinical Nutrition</i> , 2021, 40, 4316-4323.	2.3	24
658	Calcium antagonists in the treatment of ischemic heart disease. <i>Coronary Artery Disease</i> , 1994, 5, 21-26.	0.3	23
659	Dysglycemia and a History of Reproductive Risk Factors. <i>Diabetes Care</i> , 2008, 31, 1635-1638.	4.3	23
660	Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk. <i>Atherosclerosis</i> , 2013, 226, 245-251.	0.4	23
661	Modification of Outcomes With Aspirin or Apixaban in Relation to CHADS <sub>2</sub> and CHA <sub>2</sub> DS <sub>2</sub> -VASc Scores in Patients With Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 31-38.	2.1	23
662	Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. <i>European Heart Journal</i> , 2014, 35, 1743-1751.	1.0	23
663	The Cost Implications of Off-Pump Versus On-Pump Coronary Artery Bypass Graft Surgery at One Year. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1620-1625.	0.7	23
664	Methylprednisolone Does Not Reduce Persistent Pain after Cardiac Surgery. <i>Anesthesiology</i> , 2015, 123, 1404-1410.	1.3	23
665	Verapamil following uncomplicated myocardial infarction: Promising, but not proven. <i>American Journal of Cardiology</i> , 1996, 77, 421-422.	0.7	22
666	Screening for Dysglycemia in Overweight Youth Presenting for Weight Management. <i>Diabetes Care</i> , 2012, 35, 711-716.	4.3	22

#	ARTICLE	IF	CITATIONS
667	Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population. <i>Diabetes Care</i> , 2013, 36, 2836-2842.	4.3	22
668	Incremental Value of Left Ventricular Systolic and Diastolic Function to Determine Outcome in Patients with Acute STâ€Segment Elevation Myocardial Infarction: The Echocardiographic Substudy of the OASISâ€6 Trial. <i>Echocardiography</i> , 2014, 31, 569-578.	0.3	22
669	Perioperative Aspirin for Prevention of Venous Thromboembolism. <i>Anesthesiology</i> , 2016, 125, 1121-1129.	1.3	22
670	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heartâ€Failure (Part 2/5). <i>Journal of the American College of Cardiology</i> , 2019, 74, 683-698.	1.2	22
671	Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. <i>Canadian Journal of Cardiology</i> , 2003, 19, 1387-91.	0.8	22
672	The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. <i>European Heart Journal</i> , 2013, 34, 2752-2759.	1.0	21
673	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , 2016, 17, 1425-1439.	0.6	21
674	Blood HER2 and Uromodulin as Causal Mediators of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1326-1335.	3.0	21
675	Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial. <i>American Heart Journal</i> , 2019, 216, 9-19.	1.2	21
676	Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 286-295.e3.	1.2	21
677	Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis. <i>EClinicalMedicine</i> , 2022, 44, 101284.	3.2	21
678	Coronary Artery Disease in Asian Indians: Prevalence and Risk Factors. <i>Asian American and Pacific Islander Journal of Health</i> , 1993, 1, 163-175.	0.1	21
679	Identification of genetic effects underlying type 2 diabetes in South Asian and European populations. <i>Communications Biology</i> , 2022, 5, 329.	2.0	21
680	Influence of beta blockade on exercise capacity and heart rate response after human orthotopic and heterotopic cardiac transplantation. <i>American Journal of Cardiology</i> , 1989, 64, 636-641.	0.7	20
681	Albuminuria and Rapid Loss of GFR and Risk of New Hip and Pelvic Fractures. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 233-240.	2.2	20
682	Adverse health impacts of cooking with kerosene: A multi-country analysis within the Prospective Urban and Rural Epidemiology Study. <i>Environmental Research</i> , 2020, 188, 109851.	3.7	20
683	Analyses by the Intention-to-Treat Principle in Randomized Trials and Databases. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1991, 14, 2078-2082.	0.5	19
684	The HOPE study and diabetes. <i>Lancet</i> , The, 2000, 355, 1183-1184.	6.3	19

#	ARTICLE	IF	CITATIONS
685	Physical Activity Levels, Sport Activities, and Risk of Acute Myocardial Infarction. <i>Angiology</i> , 2014, 65, 113-121.	0.8	19
686	Rationale and design of a randomized controlled trial evaluating community health worker-based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD). <i>American Heart Journal</i> , 2014, 168, 690-697.	1.2	19
687	Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. <i>European Journal of Heart Failure</i> , 2014, 16, 325-333.	2.9	19
688	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	0.7	19
689	Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial. <i>Cmaj</i> , 2019, 191, E247-E256.	0.9	19
690	Challenges in the conduct and interpretation of phase II (pilot) randomized trials. <i>American Heart Journal</i> , 2000, 139, S136-S142.	1.2	18
691	Polypill: the evidence and the promise. <i>Current Opinion in Lipidology</i> , 2009, 20, 453-459.	1.2	18
692	Documenting the Global Burden of Cardiovascular Disease. <i>Circulation</i> , 2014, 129, 1459-1462.	1.6	18
693	Impact of a Genetic Risk Score on Myocardial Infarction Risk Across Different Ethnic Populations. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1440-1446.	0.8	18
694	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , 2021, 42, 2995-3007.	1.0	18
695	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	0.8	18
696	A Novel Method to Evaluate the Community Built Environment Using Photographs – Environmental Profile of a Community Health (EPOCH) Photo Neighbourhood Evaluation Tool. <i>PLoS ONE</i> , 2014, 9, e110042.	1.1	18
697	Issues regarding the use of heparin following streptokinase therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 1995, 2, 5-10.	1.0	17
698	Early Versus Delayed Enalapril in Patients With Left Ventricular Systolic Dysfunction: Impact on Morbidity and Mortality 15 Years After the SOLVD Trial. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1904-1905.	1.2	17
699	Iatrogenic Adverse Events in the Coronary Care Unit. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 437-442.	0.9	17
700	Combination Therapy to Prevent Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1595.	3.8	17
701	Why do people not take life-saving medications? The case of statins. <i>Lancet</i> , 2016, 388, 943-945.	6.3	17
702	Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <math>\leq 120/80\text{ mmHg}</math> Target?. <i>Circulation</i> , 2016, 134, 1311-1313.	1.6	17

#	ARTICLE	IF	CITATIONS
703	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. <i>Current Problems in Cardiology</i> , 2017, 42, 198-225.	1.1	17
704	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the Atrial Fibrillation Treatment Trial. <i>Journal of the American Heart Association</i> , 2019, 8, e010107.	1.6	17
705	Are large simple trials for dementia prevention possible?. <i>Age and Ageing</i> , 2020, 49, 154-160.	0.7	17
706	Cerebral small vessel disease and other influential factors of cognitive impairment in the middle-aged: a long-term observational cohort PURE-MIND study in Poland. <i>GeroScience</i> , 2021, 43, 279-295.	2.1	17
707	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. <i>Cardiovascular Research</i> , 2022, 118, 897-903.	1.8	17
708	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2726-2737.	1.9	17
709	Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Trial. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1083-1092.	1.0	16
710	Knowledge, opinions and compliance related to the 100% smoke-free law in hospitality venues in Kampala, Uganda: cross-sectional results from the KOMPLY Project. <i>BMJ Open</i> , 2018, 8, e017601.	0.8	16
711	The spectrum of the dyslipidemia in Colombia: The PURE study. <i>International Journal of Cardiology</i> , 2019, 284, 111-117.	0.8	16
712	Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation. <i>Circulation</i> , 2020, 142, 1697-1699.	1.6	16
713	Associations of household solid fuel for heating and cooking with hypertension in Chinese adults. <i>Journal of Hypertension</i> , 2021, 39, 667-676.	0.3	16
714	Cardiovascular disease in India: lessons learnt & challenges ahead. <i>Indian Journal of Medical Research</i> , 2010, 132, 529-30.	0.4	16
715	Variations in risks from smoking between high-income, middle-income, and low-income countries: an analysis of data from 179 000 participants from 63 countries. <i>The Lancet Global Health</i> , 2022, 10, e216-e226.	2.9	16
716	Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) trial. <i>American Journal of Cardiology</i> , 1999, 84, 20-25.	0.7	15
717	Damage to important clinical trials by over-regulation. <i>Clinical Trials</i> , 2010, 7, 622-625.	0.7	15
718	Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , 2010, 12, 738-745.	2.9	15
719	Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes (OASIS-6) trial. <i>American Heart Journal</i> , 2010, 160, 1049-1055.	1.2	15
720	Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit. <i>Diabetes Care</i> , 2012, 35, 19-24.	4.3	15

#	ARTICLE	IF	CITATIONS
721	The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure-“Lowering Trials. <i>JAMA Cardiology</i> , 2016, 1, 857.	3.0	15
722	Does greater individual social capital improve the management of hypertension? Cross-national analysis of 61 229 individuals in 21 countries. <i>BMJ Global Health</i> , 2017, 2, e000443.	2.0	15
723	Development, Testing, and Implementation of a Training Curriculum for Nonphysician Health Workers to Reduce Cardiovascular Disease. <i>Global Heart</i> , 2018, 13, 93.	0.9	15
724	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	1.0	15
725	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021, 117, 942-949.	1.8	15
726	One-year Results of a Factorial Randomized Trial of Aspirin <i>versus</i> Placebo and Clonidine <i>versus</i> Placebo in Patients Having Noncardiac Surgery. <i>Anesthesiology</i> , 2020, 132, 692-701.	1.3	15
727	Towards better hypertension management in India. <i>Indian Journal of Medical Research</i> , 2014, 139, 657-60.	0.4	15
728	Clinical research and trials in developing countries. <i>Statistics in Medicine</i> , 2002, 21, 2859-2867.	0.8	14
729	Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. <i>Canadian Journal of Physiology and Pharmacology</i> , 2005, 83, 98-103.	0.7	14
730	The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 96-97.	3.3	14
731	Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2009, 3, 113-121.	1.0	14
732	What information should a sponsor of a randomized trial receive during its conduct?. <i>Clinical Trials</i> , 2011, 8, 716-719.	0.7	14
733	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fondà CABG study. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 378-385.	1.0	14
734	Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?. <i>Journal of Clinical Lipidology</i> , 2013, 7, 626-631.	0.6	14
735	Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 272-280.	0.8	14
736	Prognostic Usefulness of Left Ventricular Hypertrophy by Electrocardiography in Patients With Atrial Fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). <i>American Journal of Cardiology</i> , 2014, 113, 669-675.	0.7	14
737	Global Cardiovascular Research Training for Implementation Science, Health Systems Research, and Health Policy Research. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1371-1372.	1.2	14
738	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , 2016, 140, 81-88.	0.8	14



#	ARTICLE	IF	CITATIONS
739	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. <i>American Heart Journal</i> , 2018, 198, 169-177.	1.2	14
740	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2287-2295.	1.9	14
741	COVID-19 Vaccination Prioritization on the Basis of Cardiovascular Risk Factors and Number Needed to Vaccinate to Prevent Death. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1112-1116.	0.8	14
742	Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study. <i>European Heart Journal</i> , 2022, 43, 202-209.	1.0	14
743	Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE). <i>Journal of Stroke</i> , 2022, 24, 224-235.	1.4	14
744	When It Comes to Trials, Do We Get What We Pay For?. <i>New England Journal of Medicine</i> , 2013, 369, 1962-1963.	13.9	13
745	The Effects of Steroids on Coagulation Dysfunction Induced by Cardiopulmonary Bypass: A Steroids in Cardiac Surgery (SIRS) Trial Substudy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2017, 29, 35-44.	0.4	13
746	Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. <i>Canadian Journal of Cardiology</i> , 2018, 34, 38-44.	0.8	13
747	The Effect of Steroids in Patients Undergoing Cardiopulmonary Bypass: An Individual Patient Meta-Analysis of Two Randomized Trials. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2020, 34, 99-105.	0.6	13
748	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , 2020, 22, 870-877.	0.7	13
749	New-Onset Perioperative Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Risk of Adverse Events: An Analysis From the CORONARY Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e020426.	1.6	13
750	Effect of Cognitive Reserve on the Association of Vascular Brain Injury With Cognition. <i>Neurology</i> , 2021, 97, e1707-e1716.	1.5	13
751	Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?. <i>European Heart Journal</i> , 2006, 27, 2154-2157.	1.0	12
752	Factors of Importance for QRS Complex Recovery after Acute Myocardial Infarction. <i>Acta Medica Scandinavica</i> , 1982, 211, 157-162.	0.0	12
753	The Indian Polycap Study (TIPS) — Authors' reply. <i>Lancet</i> , The, 2009, 374, 782.	6.3	12
754	In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events. <i>PLoS ONE</i> , 2010, 5, e13694.	1.1	12
755	Body-mass index, abdominal adiposity, and cardiovascular risk. <i>Lancet</i> , The, 2011, 378, 226-227.	6.3	12
756	Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY): kidney substudy analytic protocol of an international randomised controlled trial. <i>BMJ Open</i> , 2012, 2, e001080.	0.8	12

#	ARTICLE	IF	CITATIONS
757	How Robust Is the Evidence for Recommending Very Low Salt Intake in Entire Populations? —. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1618-1621.	1.2	12
758	Mendelian Genes and Risk of Intracerebral Hemorrhage and Small-Vessel Ischemic Stroke in Sporadic Cases. <i>Stroke</i> , 2017, 48, 2263-2265.	1.0	12
759	Digoxin and clinical outcomes in the Global Rheumatic Heart Disease Registry. <i>Heart</i> , 2019, 105, heartjnl-2018-313614.	1.2	12
760	Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk. <i>Diabetes Care</i> , 2019, 42, 1800-1808.	4.3	12
761	Air pollution health impacts: the knowns and unknowns for reliable global burden calculations. <i>Cardiovascular Research</i> , 2020, 116, 1794-1796.	1.8	12
762	The effect of treatment on survival in congestive heart failure. <i>Clinical Cardiology</i> , 1992, 15, 323-329.	0.7	11
763	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. <i>Thrombosis Research</i> , 2010, 125, e128-e131.	0.8	11
764	The Fluid Study Protocol: A Randomized Controlled Study on the Effects of Bioimpedance Analysis and Vitamin D on Left Ventricular Mass in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2011, 31, 529-536.	1.1	11
765	The Cost of Clopidogrel Use in Atrial Fibrillation in the ACTIVE-A Trial. <i>Canadian Journal of Cardiology</i> , 2012, 28, 95-101.	0.8	11
766	The cost implications of an early versus delayed invasive strategy in acute coronary syndromes: the TIMACS study. <i>Journal of Medical Economics</i> , 2014, 17, 415-422.	1.0	11
767	The Population Risks of Dietary Salt Excess Are Exaggerated. <i>Canadian Journal of Cardiology</i> , 2014, 30, 507-512.	0.8	11
768	Modification of Outcomes With Aspirin or Apixaban in Relation to Female and Male Sex in Patients With Atrial Fibrillation. <i>Stroke</i> , 2014, 45, 2127-2130.	1.0	11
769	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation—the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study. <i>Europace</i> , 2018, 20, 253-262.	0.7	11
770	Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study. <i>American Heart Journal</i> , 2018, 203, 57-66.	1.2	11
771	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019, 14, 270-281.	2.9	11
772	Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 692-700.	0.5	11
773	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021, 77, 511-525.	1.2	11
774	Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e891-e898.	1.8	11

#	ARTICLE	IF	CITATIONS
775	Association of bedtime with mortality and major cardiovascular events: an analysis of 112,198 individuals from 21 countries in the PURE study. <i>Sleep Medicine</i> , 2021, 80, 265-272.	0.8	11
776	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2021, 149, 27-35.	0.7	11
777	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2022, 21, 12.	2.7	11
778	The role of digitalis in the treatment of heart failure. <i>Coronary Artery Disease</i> , 1999, 10, 353-360.	0.3	10
779	Transforming the scientific, health care, and sociopolitical culture of an entire country through clinical research: The story of GISSI. <i>American Heart Journal</i> , 2004, 148, 193-195.	1.2	10
780	Impact of Ramipril on the Circadian Periodicity of Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2006, 98, 758-760.	0.7	10
781	Deciphering the Causes of Cardiovascular and Other Complex Diseases in Populations: Achievements, Challenges, Opportunities, and Approaches. <i>Progress in Cardiovascular Diseases</i> , 2010, 53, 62-67.	1.6	10
782	CANadian Network and Centre for Trials Internationally (CANNeCTIN): A national network for Canadian-led trials in cardiovascular diseases and diabetes mellitus. <i>Canadian Journal of Cardiology</i> , 2010, 26, 353-358.	0.8	10
783	Off-Pump or On-Pump Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , 2013, 369, 194-197.	13.9	10
784	Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial. <i>BMJ Open</i> , 2014, 4, e004842.	0.8	10
785	Measuring Sodium Intake in Populations: Simple Is Best?. <i>American Journal of Hypertension</i> , 2015, 28, 1303-1305.	1.0	10
786	Physical Activity to Prevent Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 1358.	3.0	10
787	Insulin resistance and cardiovascular outcomes in the <scp>ORIGIN</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 564-570.	2.2	10
788	Evolving evidence about diet and health. <i>Lancet Public Health</i> , The, 2018, 3, e408-e409.	4.7	10
789	Associations of cardiometabolic outcomes with indices of obesity in children aged 5 years and younger. <i>PLoS ONE</i> , 2019, 14, e0218816.	1.1	10
790	Reducing Cardiovascular Disease Globally: The World Heart Federation's Roadmaps. <i>Global Heart</i> , 2015, 10, 93.	0.9	10
791	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , 2021, 52, 2494-2501.	1.0	10
792	Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study. <i>Gastroenterology</i> , 2021, 161, 1333-1335.e1.	0.6	10

#	ARTICLE	IF	CITATIONS
793	Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery. <i>Trials</i> , 2022, 23, 101.	0.7	10
794	Mitochondrial DNA Copy Number as a Marker and Mediator of Stroke Prognosis. <i>Neurology</i> , 2022, 98, .	1.5	10
795	Limitation of Myocardial Infarct Size Present Status. <i>Drugs</i> , 1983, 25, 441-450.	4.9	9
796	Effect of acute angiotensin converting enzyme inhibition on left ventricular diastolic filling in patients with congestive heart failure: Relation to right ventricular volume. <i>Journal of the American College of Cardiology</i> , 1990, 15, A210.	1.2	9
797	Neurohumoral variability in left ventricular dysfunction. <i>American Journal of Cardiology</i> , 1995, 75, 354-359.	0.7	9
798	Factors influencing exercise performance in patients with left ventricular dysfunction. <i>Journal of Cardiac Failure</i> , 1998, 4, 159-167.	0.7	9
799	Management of Stable Coronary Disease. <i>New England Journal of Medicine</i> , 2007, 357, 1762-1766.	13.9	9
800	Extreme Sodium Reductions for the Entire Population: Zealotry or Evidence Based?. <i>American Journal of Hypertension</i> , 2013, 26, 1187-1190.	1.0	9
801	Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. <i>Diabetologia</i> , 2014, 57, 738-745.	2.9	9
802	Influence of Tea Consumption on Acute Myocardial Infarction in China Population. <i>Angiology</i> , 2015, 66, 265-270.	0.8	9
803	Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial. <i>New England Journal of Medicine</i> , 2016, 375, 1190-1194.	13.9	9
804	Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , 2017, 376, 894-895.	13.9	9
805	Doubleâ€Dose Versus Standardâ€Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	9
806	Varying Effects of Body Mass Index and Mortality in Different Risk Groups. <i>American Journal of Cardiology</i> , 2018, 122, 1155-1160.	0.7	9
807	Can We Eliminate Rheumatic Fever and Premature Deaths From RHD?. <i>Global Heart</i> , 2020, 12, 3.	0.9	9
808	Reduced Cognitive Assessment Scores Among Individuals With Magnetic Resonance Imagingâ€Detected Vascular Brain Injury. <i>Stroke</i> , 2020, 51, 1158-1165.	1.0	9
809	Sodium and health: another challenge to the current dogma. <i>European Heart Journal</i> , 2021, 42, 2116-2118.	1.0	9
810	Measuring sodium intake: research and clinical applications. <i>Journal of Hypertension</i> , 2021, 39, 2344-2352.	0.3	9

#	ARTICLE	IF	CITATIONS
811	What Is the Economic Value of Digoxin Therapy in Congestive Heart Failure Patients? Results From the DIG Trial. <i>Journal of Cardiac Failure</i> , 2006, 12, 336-342.	0.7	8
812	Stroke and Cardiovascular Diseases: The Need for a Global Approach for Prevention and Drug Development. <i>International Journal of Stroke</i> , 2007, 2, 104-108.	2.9	8
813	Cigarette pack labelling in 12 countries at different levels of economic development. <i>Journal of Public Health Policy</i> , 2011, 32, 146-164.	1.0	8
814	Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial. <i>Blood Pressure</i> , 2014, 23, 54-60.	0.7	8
815	Challenges to conducting epidemiology research in chronic conflict areas: examples from PURE-Palestine. <i>Conflict and Health</i> , 2016, 10, 33.	1.0	8
816	Commentary: Accepting what we don't know will lead to progress. <i>International Journal of Epidemiology</i> , 2016, 45, 260-262.	0.9	8
817	Effective approaches to address the global cardiovascular disease burden. <i>Current Opinion in Cardiology</i> , 2017, 32, 557-566.	0.8	8
818	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. <i>Thrombosis and Haemostasis</i> , 2021, 121, 518-528.	1.8	8
819	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 462-473.	1.4	8
820	The repeatability of self reported physical activity patterns in rural South India. <i>Asia Pacific Journal of Clinical Nutrition</i> , 2009, 18, 71-5.	0.3	8
821	Oral Anticoagulant Therapy in Patients with Coronary Artery Disease. <i>Seminars in Vascular Medicine</i> , 2003, 03, 323-332.	2.1	7
822	Corrigendum to "Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis" [ <i>Eur J Heart Fail</i> 7 (2005) 1133-1144]. <i>European Journal of Heart Failure</i> , 2006, 8, 223-224.	2.9	7
823	Unresolved Issues in the Management of Hypertension. <i>Hypertension</i> , 2010, 55, 832-834.	1.3	7
824	Fine Mapping of the Insulin-Induced Gene 2 Identifies a Variant Associated With LDL Cholesterol and Total Apolipoprotein B Levels. <i>Circulation: Cardiovascular Genetics</i> , 2010, 3, 454-461.	5.1	7
825	Is therapy of people with chronic kidney disease ONTARGET?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 42-44.	0.4	7
826	Risk factors for stroke in Tanzania. <i>The Lancet Global Health</i> , 2013, 1, e241-e242.	2.9	7
827	Impact of lifestyle factors on fracture risk in older patients with cardiovascular disease: a prospective cohort study of 26,335 individuals from 40 countries. <i>Age and Ageing</i> , 2014, 43, 629-635.	0.7	7
828	Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2682-2689.	1.8	7

#	ARTICLE	IF	CITATIONS
829	Could patents interfere with the development of a cardiovascular polypill?. <i>Journal of Translational Medicine</i> , 2016, 14, 242.	1.8	7
830	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1332-1339.	0.8	7
831	Polypill Variants (Quarter Pill Trials). <i>American Journal of Hypertension</i> , 2018, 31, 758-761.	1.0	7
832	Graphical comparisons of relative disease burden across multiple risk factors. <i>BMC Medical Research Methodology</i> , 2019, 19, 186.	1.4	7
833	Low levels of awareness, treatment, and control of hypertension in Andean communities of Ecuador. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1530-1537.	1.0	7
834	Reducing Premature Cardiovascular Mortality By 2025: The World Heart Federation Roadmap. <i>Global Heart</i> , 2020, 10, 97.	0.9	7
835	Adapting the World Heart Federation Roadmaps at the National Level: Next Steps and Conclusions. <i>Global Heart</i> , 2020, 10, 135.	0.9	7
836	Associations of estimated 24-h urinary sodium excretion with mortality and cardiovascular events in Chinese adults: a prospective cohort study. <i>Journal of Hypertension</i> , 2021, 39, 484-493.	0.3	7
837	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. <i>Blood</i> , 2012, 120, 19-19.	0.6	7
838	Multinational prediction of household and personal exposure to fine particulate matter (PM2.5) in the PURE cohort study. <i>Environment International</i> , 2022, 159, 107021.	4.8	7
839	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial. <i>European Heart Journal</i> , 2022, 43, 3542-3552.	1.0	7
840	ATENOLOL, HEPARIN AND THE INTERMEDIATE CORONARY SYNDROME. <i>Lancet</i> , The, 1981, 318, 46.	6.3	6
841	The impact of left ventricular dysfunction on outcomes with the implantable defibrillator. <i>American Heart Journal</i> , 1994, 127, 1159-1163.	1.2	6
842	Role of infarct size in explaining the higher mortality in older patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2002, 90, 1370-1374.	0.7	6
843	The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study. <i>Journal of Medical Economics</i> , 2011, 14, 792-797.	1.0	6
844	Low sodium intake and cardiovascular health: an unanswered question. Response to: Letter from Dr N. Campbell, "Dissidents and dietary sodium. Concerns about the commentary by O'Donnelle et al." <i>International Journal of Epidemiology</i> , 2016, 46, dyw297.	0.9	6
845	Gene Expression Profiles for the Identification of Prevalent Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	6
846	Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 681-697.	0.8	6



#	ARTICLE	IF	CITATIONS
847	Diet and health: the need for new and reliable approaches. <i>European Heart Journal</i> , 2020, 41, 2641-2644.	1.0	6
848	Urinary Sodium and Potassium, and Risk of Ischemic and Hemorrhagic Stroke (INTERSTROKE): A Caseâ€“Control Study. <i>American Journal of Hypertension</i> , 2021, 34, 414-425.	1.0	6
849	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.	1.2	6
850	Pericardial Disease: An Evidence-Based Approach to Diagnosis and Treatment. , 0, , 735-748.		6
851	Population Muscle Strength Predicts Olympic Medal Tallies: Evidence from 20 Countries in the PURE Prospective Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0169821.	1.1	6
852	Impact of Bioelectrical Impedanceâ€“Guided Fluid Management and Vitamin D Supplementation on Left Ventricular Mass in Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2022, 79, 820-831.	2.1	6
853	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	1.4	6
854	Renin response to sympathetic stimulation in cyclosporin-treated heart-transplant patients. <i>American Journal of Cardiology</i> , 1989, 63, 1142-1144.	0.7	5
855	Risk-Benefit Assessment of Antiarrhythmic Drugs. <i>Drug Safety</i> , 1991, 6, 323-331.	1.4	5
856	Effects of ACE Inhibitors on Mortality When Started in the Early Phase of Myocardial Infarction: Evidence from the Larger Randomized Controlled Trials. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 423-428.	3.1	5
857	Cardiovascular Outcomes and Renal Disease. <i>Annals of Internal Medicine</i> , 2002, 136, 634.	2.0	5
858	Association of the FABP2 T54 Variant with Plasma Triglycerides and Insulin Resistance in a Multiethnic Population. <i>Clinical Chemistry</i> , 2008, 54, 1742-1744.	1.5	5
859	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2885-2886.	1.2	5
860	Associations of fats and carbohydrates with cardiovascular disease and mortalityâ€“PURE and simple? â€“ Authors' reply. <i>Lancet</i> , The, 2018, 391, 1681-1682.	6.3	5
861	Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2769-2772.	1.2	5
862	Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. <i>Europace</i> , 2019, 21, 1023-1030.	0.7	5
863	Psychosocial Factors in the Primary and Secondary Prevention of Coronary Heart Disease: An Updated Systematic Review of Prospective Cohort Studies. , 0, , 181-218.		5
864	Personal and household PM2.5 and black carbon exposure measures and respiratory symptoms in 8 low- and middle-income countries. <i>Environmental Research</i> , 2022, 212, 113430.	3.7	5

#	ARTICLE	IF	CITATIONS
865	The likelihood ratio versus the p value in meta-analysis: Where is the evidence?. Contemporary Clinical Trials, 1989, 10, 205-208.	2.0	4
866	Randomized Trials to Assess the Long-term Effects of Therapies on Angiographic End Points. Chest, 1991, 99, 1243-1247.	0.4	4
867	Intracranial haemorrhage with bolus thrombolytic agents. Lancet, The, 2000, 356, 1850.	6.3	4
868	Management of myocardial infarction: looking beyond efficacy—Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology, 2000, 35, 380-381.	1.2	4
869	The CHARM programme. Lancet, The, 2003, 362, 1678-1679.	6.3	4
870	Enhancing Risk Prediction With PET Coronary Flow Reserve. JACC: Cardiovascular Imaging, 2012, 5, 1035-1036.	2.3	4
871	Impact of access to hospitals with catheterization facilities in the second Gulf Registry of Acute Coronary Events (Gulf RACE-2). Coronary Artery Disease, 2013, 24, 412-418.	0.3	4
872	Cardiovascular Risk and Events and Country Income Stratum. New England Journal of Medicine, 2015, 372, 288-290.	13.9	4
873	The epidemic of cardiovascular disease in South Asians: Time for action. American Heart Journal, 2017, 185, 150-153.	1.2	4
874	Risks of Overinterpreting Interim Data. Circulation, 2018, 137, 206-209.	1.6	4
875	Exploring New Models for Cardiovascular Risk Reduction: The Heart Outcomes Prevention and Evaluation 4 (HOPE 4) Canada Pilot Study. CJC Open, 2021, 3, 267-275.	0.7	4
876	Prevalence of metabolic syndrome and diabetes mellitus type-2 and their association with intake of dairy and legume in Andean communities of Ecuador. PLoS ONE, 2021, 16, e0254812.	1.1	4
877	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. International Journal of Cardiology, 2021, 337, 9-15.	0.8	4
878	LVSâ€œHARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a Worldâ€œWide Registry. Journal of the American Heart Association, 2021, 10, e017735.	1.6	4
879	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. CJC Open, 2022, 4, 568-576.	0.7	4
880	A Critical Appraisal of the Cardiovascular History and Physical Examination. , 0, , 14-23.		4
881	Factors associated with healthâ€œrelated quality of life in heart failure in 23,000 patients from 40 countries: Results of the <sc>Gâ€œCHF</sc> Research Program. European Journal of Heart Failure, 2022, , .	2.9	4
882	Independent design and conduct of clinical trials. Clinical Trials, 2006, 3, 503-507.	0.7	3

#	ARTICLE	IF	CITATIONS
883	Commentary: 'The end of clinical freedom': relevance in the era of evidence-based medicine. International Journal of Epidemiology, 2011, 40, 855-858.	0.9	3
884	Reducing cardiovascular mortality through lifestyle change in Japan. European Heart Journal, 2012, 33, 428-429.	1.0	3
885	Corrigendum to "Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved" [Eur J Heart Fail 2014;16:33-40]. European Journal of Heart Failure, 2014, 16, 592-592.	2.9	3
886	Response to Letter Regarding Article, "Causes of Death and Influencing Factors in Patients With Atrial Fibrillation: A Competing-Risk Analysis From the Randomized Evaluation of Long-Term Anticoagulant Therapy Study" Circulation, 2014, 130, e85.	1.6	3
887	A 35-year journey to evidence-based medicine: a personal story. European Heart Journal, 2015, 36, 3460-3466.	1.0	3
888	Improving worldwide access to inexpensive and effective treatments for common cardiovascular diseases. European Heart Journal Supplements, 2018, 20, C18-C22.	0.0	3
889	Response to: "More on dissidents and dietary sodium". International Journal of Epidemiology, 2018, 47, 673-674.	0.9	3
890	Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetes, Obesity and Metabolism, 2019, 21, 1502-1505.	2.2	3
891	Access to Essential Medicines for Circulatory Diseases: A Call to Action. Global Heart, 2019, 14, 399.	0.9	3
892	The Indirect Consequences of the Response to the COVID-19 Pandemic. Journal of the American College of Cardiology, 2021, 77, 186-188.	1.2	3
893	The risk of cardiovascular events in patients with metabolic syndrome: The results of a population based prospective cohort study (PURE Turkey). Anatolian Journal of Cardiology, 2020, 24, 192-200.	0.5	3
894	Variations in the association of height with mortality, cardiovascular disease and cancer in low-, middle- and high-income countries. International Journal of Epidemiology, 2022, 51, 1304-1316.	0.9	3
895	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 837-838.		3
896	From journal to bedside: quantifying the benefits of treatment. Evidence-based Cardiovascular Medicine, 1997, 1, 57-58.	0.0	2
897	Blood pressure and cardiovascular risk in the HOPE study. Lancet, The, 2002, 359, 2118.	6.3	2
898	Who is fooling us?. Lancet, The, 2002, 360, 873-874.	6.3	2
899	Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 798-799.	2.9	2
900	The Editor's Roundtable: Arterial Thrombosis and Acute Coronary Syndromes. American Journal of Cardiology, 2007, 100, 974-980.	0.7	2

#	ARTICLE	IF	CITATIONS
901	Response to Letters Regarding Article, "Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin: Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial" Circulation, 2013, 127, e506.	1.6	2
902	Sodium and cardiovascular disease " Authors' reply. Lancet, The, 2016, 388, 2113-2114.	6.3	2
903	Response by Smyth et al to Letters Regarding Article, "Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study" Circulation, 2017, 135, e644-e645.	1.6	2
904	Facing cardiovascular risk in Ibero-America. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 799-801.	0.4	2
905	Eggs and diabetes: 1 daily egg a safe bet?. American Journal of Clinical Nutrition, 2020, 112, 503-504.	2.2	2
906	Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study. Neuroepidemiology, 2021, 55, 206-215.	1.1	2
907	Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction. , 0, , 397-425.		2
908	Restenosis: Etiologies and Prevention. , 0, , 371-394.		2
909	Measuring and predicting personal and household Black Carbon levels from 88 communities in eight countries. Science of the Total Environment, 2022, 818, 151849.	3.9	2
910	Differences and agreement between two portable hand-held spirometers across diverse community-based populations in the Prospective Urban Rural Epidemiology (PURE) study. PLOS Global Public Health, 2022, 2, e0000141.	0.5	2
911	Polypharmacotherapy for primary prevention of cardiovascular disease. Indian Heart Journal, 2008, 60, B29-33.	0.2	2
912	Medications for blood pressure, blood glucose, lipids, and anti-thrombotic medications: relationship with cardiovascular disease and death in adults from 21 high-, middle-, and low-income countries with an elevated body mass index. European Journal of Preventive Cardiology, 2022, 29, 1817-1826.	0.8	2
913	Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106404.	0.7	2
914	The cost implications of a polypill for primary prevention in the TIPS-3 trial. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 899-908.	1.8	2
915	Tobacco and Cardiovascular Disease: Achieving Smoking Cessation. , 0, , 114-120.		2
916	Indications for Surgery in Aortic Valve Disease. , 0, , 767-781.		2
917	Diagnosis and Management of Infective Endocarditis. , 0, , 817-831.		2
918	Antithrombotic Therapy after Heart Valve Replacement. , 0, , 832-836.		2

#	ARTICLE	IF	CITATIONS
919	The Prevalence and Risk Factors Associated with Iodine Deficiency in Canadian Adults. <i>Nutrients</i> , 2022, 14, 2570.	1.7	2
920	Randomized Clinical Trials in Heart Disease-Reply. <i>JAMA - Journal of the American Medical Association</i> , 1989, 261, 2953.	3.8	1
921	From journal to bedside: obtaining medically useful answers from a meta-analysis. <i>Evidence-based Cardiovascular Medicine</i> , 1997, 1, 85-86.	0.0	1
922	From journal to bedside: application of clinical trial results to individual patients. <i>Evidence-based Cardiovascular Medicine</i> , 1997, 1, 29-31.	0.0	1
923	Evidence-based cardiovascular medicine: Why another journal?. <i>Evidence-based Cardiovascular Medicine</i> , 1997, 1, 1.	0.0	1
924	Meta-analysis. <i>Lancet, The</i> , 1998, 351, 1960.	6.3	1
925	Management of unstable angina and myocardial infarction. <i>Lancet, The</i> , 2000, 356, 1193-1194.	6.3	1
926	The value of large, robust trials: the HOPE study. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2002, 19, 29-30.	0.2	1
927	Commentary: Insights from cross-population studies: Rose revisited. <i>International Journal of Epidemiology</i> , 2005, 34, 244-246.	0.9	1
928	Risk Factors for Early Myocardial Infarction in South Asians—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 1880.	3.8	1
929	Renal outcomes in the ONTARGET study — Authors' reply. <i>Lancet, The</i> , 2008, 372, 2020-2021.	6.3	1
930	Which antithrombotic to use during PCI?. <i>European Heart Journal</i> , 2010, 31, 522-524.	1.0	1
931	Preface: Reflections on a Career in Health Research, International Collaboration and Mentoring. <i>Public Health Reviews</i> , 2011, 33, 363-372.	1.3	1
932	Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy" <i>Circulation</i> , 2013, 127, e278-9.	1.6	1
933	Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Trial" <i>Circulation</i> , 2013, 127, e278-9.	1.6	1
934	On the economics of managing blood pressure. <i>Lancet, The</i> , 2017, 389, 1294-1295.	6.3	1
935	WHF Emerging Leaders Program. <i>European Heart Journal</i> , 2017, 38, 2800-2803.	1.0	1
936	Adiposity and mortality in South Asians: challenges to the existing paradigm. <i>The Lancet Global Health</i> , 2018, 6, e712-e713.	2.9	1

#	ARTICLE	IF	CITATIONS
937	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	1
938	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. <i>Canadian Journal of Cardiology</i> , 2019, 35, 644-652.	0.8	1
939	Developing the Core Pillars of Training Global Cardiovascular Health Researchers: Companionship, Light, and Fuel. <i>Global Heart</i> , 2020, 14, 387.	0.9	1
940	What is the Association Between Depression and Cardiovascular Disease? Reply. <i>JAMA Psychiatry</i> , 2020, 77, 1308.	6.0	1
941	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , 2020, 15, e0226259.	1.1	1
942	Leaders in Cardiovascular Research: Salim Yusuf. <i>Cardiovascular Research</i> , 2020, 116, e26-e28.	1.8	1
943	Causal ordering among risk factors in the PURE study – Authors' reply. <i>Lancet</i> , The, 2021, 397, 279.	6.3	1
944	Blood Pressure and Cardiovascular Disease. , 0, , 146-160.		1
945	The Fetal Origins of Coronary Heart Disease. , 0, , 279-286.		1
946	Management of Overt Heart Failure. , 0, , 659-680.		1
947	Bongani Mayosi, a hero remembered. <i>Cardiovascular Journal of Africa</i> , 2018, 29, 206.	0.2	1
948	OUP accepted manuscript. <i>European Heart Journal</i> , 2022, , .	1.0	1
949	CardioPulse: Prevention of global cardiovascular disease. <i>European Heart Journal</i> , 2016, 37, 505-7.	1.0	1
950	Tobacco: Global Burden and Community Solutions. , 0, , 103-113.		1
951	Anti-Ischemic Drugs. , 0, , 329-338.		1
952	Prevention and Treatment of Life-Threatening Ventricular Arrhythmia and Sudden Death. , 0, , 577-586.		1
953	Finding Current Best Evidence to Practice Evidence-Based Cardiology. , 0, , 40-45.		1
954	Rheumatic Heart Disease: Prevention and Acute Treatment. , 0, , 751-757.		1



#	ARTICLE	IF	CITATIONS
955	Assessing and Changing Cardiovascular Clinical Practices. , 0, , 71-88.		1
956	Global Perspective on Cardiovascular Disease. , 0, , 91-102.		1
957	Intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI. ACP Journal Club, 2005, 143, 43.	0.1	1
958	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation, 2022, 145, 1875-1877.	1.6	1
959	The use of an FDA-NDA database to assess the risk of exposing patients with chronic stable angina to placebo-controlled trials. Contemporary Clinical Trials, 1988, 9, 249-250.	2.0	0
960	Impact of therapy on mortality and morbidity in patients with cardiac failure and left ventricular dysfunction. Journal of Molecular and Cellular Cardiology, 1990, 22, S148-S149.	0.9	0
961	A53 Factors predicting employment and job satisfaction in patients with severe left ventricular dysfunction. Contemporary Clinical Trials, 1993, 14, 420.	2.0	0
962	Discussion I. Journal of the American College of Cardiology, 1993, 22, A20-A21.	1.2	0
963	Discussion VII. Journal of the American College of Cardiology, 1993, 22, A162-A164.	1.2	0
964	Discussion IX. Journal of the American College of Cardiology, 1993, 22, A192-A193.	1.2	0
965	Selection of patients for angiography following myocardial infarction was not based on risk but on young age and availability of angiographic facilities. Evidence-based Cardiovascular Medicine, 1997, 1, 52.	0.0	0
966	Homocysteine and cardiovascular risk: is it time to treat?. Evidence-based Cardiovascular Medicine, 1999, 3, 59-60.	0.0	0
967	Recommendations for national and local regulatory authorities concerning research in genetic markers of disease. American Heart Journal, 2000, 140, S3-S5.	1.2	0
968	INTERHEART. Lancet, The, 2005, 365, 119-120.	6.3	0
969	Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarctionâ€”Reply. JAMA - Journal of the American Medical Association, 2006, 296, 2087.	3.8	0
970	Response to Letter Regarding Article, â€œThe Inflammatory Hypothesis: Any Progress in Risk Stratification and Therapeutic Targets?â€ Circulation, 2007, 115, .	1.6	0
971	Response to Letter Regarding Article, â€œDifferential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarctionâ€. Circulation, 2010, 122, .	1.6	0
972	Nutrition, tobacco use, and physical activity in the West Bank, occupied Palestinian territory: an environmental profile of community health. Lancet, The, 2012, 380, S34.	6.3	0

#	ARTICLE	IF	CITATIONS
973	Response to Letter Regarding Article, "Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin". <i>Circulation</i> , 2014, 130, e95.	1.6	0
974	The Preventive Potential of Common, Easily Measured Risk Factors for Cardiovascular Disease. <i>Clinical Chemistry</i> , 2014, 60, 1450-1451.	1.5	0
975	Obesity Genes and Risk of Major Depression in a Multiethnic Population. <i>Canadian Journal of Diabetes</i> , 2015, 39, S27.	0.4	0
976	Extra-Cardiac Disease Burden Contributes More Than Cardiac Disease Burden to Risk of Cardiovascular Outcomes in Patient with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2016, 22, S65-S66.	0.7	0
977	The INTERSTROKE study on risk factors for stroke " Authors' reply. <i>Lancet</i> , The, 2017, 389, 36.	6.3	0
978	Imaging Asymptomatic Individuals for Coronary Disease ". <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 318-320.	2.3	0
979	Joint Communication from Davos Cardiology Update, February 2017. <i>European Heart Journal</i> , 2017, 38, 1188-1188.	1.0	0
980	Rivaroxaban with or without aspirin for prevention of cardiovascular disease. <i>Coronary Artery Disease</i> , 2018, 29, 361-365.	0.3	0
981	The MANAGE trial " Authors' reply. <i>Lancet</i> , The, 2019, 393, 228.	6.3	0
982	Reply. <i>Gastroenterology</i> , 2020, 158, 285-286.	0.6	0
983	Cardiovascular risk in hypertension: open questions about HOPE 4 " Authors' reply. <i>Lancet</i> , The, 2020, 396, 310-311.	6.3	0
984	Peter Sleight. <i>Lancet</i> , The, 2020, 396, 1483.	6.3	0
985	Fishing for an Association With Sudden Cardiac Death"Reply. <i>JAMA Internal Medicine</i> , 2021, 181, 1140.	2.6	0
986	Design of trials to evaluate antiplatelet agents. , 2002, , 1003-1012.		0
987	Peter Sleight, Emeritus Professor of Cardiovascular Medicine, Oxford University, Chairman of the ISIS Trials Steering Committee. <i>European Heart Journal</i> , 2021, 42, 221-223.	1.0	0
988	A cardiovascular study that includes a million subjects. <i>European Heart Journal</i> , 2013, 34, 945-6.	1.0	0
989	Use of Lipid Lowering Agents in the Prevention of Cardiovascular Disease. , 0, , 130-145.		0
990	Glucose Abnormalities and Cardiovascular Disease:"Dysglycemia"as an Emerging Cardiovascular Risk Factor. , 0, , 161-169.		0

#	ARTICLE	IF	CITATIONS
991	Physical Activity and Exercise in Cardiovascular Disease Prevention and Rehabilitation. , 0 , 170-180.		0
992	Postmenopausal Hormone Therapy and Cardiovascular Disease. , 0 , 244-258.		0
993	Molecular Genetics of Cardiovascular Disorders. , 0 , 287-299.		0
994	Cost Effectiveness of Prevention of Cardiovascular Disease. , 0 , 300-308.		0
995	Diet and Cardiovascular Disease. , 0 , 309-325.		0
996	Adjunctive Medical Therapy in Percutaneous Coronary Intervention. , 0 , 360-370.		0
997	Obtaining Incremental Information from Diagnostic Tests. , 0 , 24-33.		0
998	Fibrinolytic Therapy. , 0 , 426-443.		0
999	Mechanical Reperfusion Strategies in Patients Presenting with Acute Myocardial Infarction. , 0 , 444-455.		0
1000	Adjunctive Antithrombotic Therapy for St-Elevation Acute Myocardial Infarction. , 0 , 456-476.		0
1001	Pain Relief, General Management, and Other Adjunctive Treatments. , 0 , 477-487.		0
1002	An Integrated Approach to the Management of Patients After the Early Phase of the Acute Coronary Syndromes. , 0 , 507-516.		0
1003	Atrial Fibrillation: Antiarrhythmic Therapy. , 0 , 519-547.		0
1004	Atrial Fibrillation: Antithrombotic Therapy. , 0 , 548-555.		0
1005	Atrial Fibrillation: Non-Pharmacologic Therapies. , 0 , 556-566.		0
1006	Clinical Trials and Meta-Analysis. , 0 , 34-39.		0
1007	Impact of Pacemakers: When and What Kind?. , 0 , 587-618.		0
1008	Acute Myocarditis and Dilated Cardiomyopathy. , 0 , 681-702.		0

#	ARTICLE	IF	CITATIONS
1009	Other Cardiomyopathies. , 0, , 718-732.		0
1010	Mitral Valve Disease: Indications for Surgery. , 0, , 758-766.		0
1011	Balloon Valvuloplasty: Aortic Valve. , 0, , 782-795.		0
1012	Balloon Valvuloplasty: Mitral Valve. , 0, , 796-808.		0
1013	Valve Repair and Choice of Valves. , 0, , 809-816.		0
1014	Treatment of Patients with Stroke. , 0, , 839-852.		0
1015	Understanding Concepts Related to Health Economics. , 0, , 46-55.		0
1016	Heart Disease and Pregnancy. , 0, , 853-863.		0
1017	Venous Thromboembolic Disease. , 0, , 864-876.		0
1018	Stable Angina: Choice of PCIv CABGv Drugs. , 0, , 892-895.		0
1019	Postmyocardial Infarction: Preventive Measures. , 0, , 906-908.		0
1020	Metabolic Risk and Secondary Prevention of Coronary Disease. , 0, , 909-911.		0
1021	Peripheral Vascular Disease with Suspect Coronary Artery Disease. , 0, , 912-914.		0
1022	Introduction to Decision Analysis. , 0, , 56-70.		0
1023	Ventricular Dysrhythmias: Pharmacologicv Non-Pharmacologic Treatment. , 0, , 925-930.		0
1024	Bradyarrhythmias: Choice of Pacemaker. , 0, , 931-933.		0
1025	Valvular Heart Disease: Timing of Surgery. , 0, , 934-937.		0
1026	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 1-2.		0

#	ARTICLE	IF	CITATIONS
1027	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 887-888.		0
1028	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 89-90.		0
1029	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 327-328.		0
1030	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 395-396.		0
1031	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 517-518.		0
1032	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 575-576.		0
1033	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 641-642.		0
1034	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 733-734.		0
1035	Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology. , 0, , 749-750.		0